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Abstract
The renin-angiotensin system (RAS) is involved in maintenance o f cardiovascular 
function and has been implicated in coronary heart disease (CHD) and type 2 diabetes 
(T2D). Pharmacological inhibition of the RAS improves cardiovascular disease 
outcomes. Angiotensin Converting Enzyme (principal component of RAS) levels are 
significantly associated with the /1C£(I/D) polymorphism. Large studies have 
demonstrated a mild effect o f this polymorphism on CHD risk. However the presence of 
RAS in diverse tissues implicated in cardiovascular diseases justify the hypothesis that 
genetic polymorphisms encoding proteins in this system ‘modify’ the risk o f such 
diseases in the context of harmful stimuli or affect disease progression.
This thesis therefore tested the hypothesis that the ACE{\JU) polymorphism ‘modifies’ 
risk of CHD and T2D, and affects progression o f Hypertrophic Cardiomyopathy 
(HCM). Using a study of 532 myocardial infarction (MI) survivors and 574 controls 
(HIFMECH), an interaction between the ACE  polymorphism and lipid levels on MI risk 
in Northern compared to Southern Europeans is demonstrated: the MI odds with high 
ApoB levels in D allele carriers was much greater in the North than the South. In a 
prospective cohort o f 3052 healthy men (NPHS2), an interaction between ACE  and 
systolic blood pressure (SBP) on CHD risk is presented where D allele carriers were 
protected against CHD at lower SBP, but at higher SBP were more susceptible. In the 
same study, ACE  variants modified the risk o f T2D in obese individuals, with obese D 
allele carriers having a substantially higher T2D risk compared to obese II 
homozygotes. From a retrospective study o f 541 patients with HCM a possible effect o f 
the polymorphism on left ventricular remodelling is demonstrated.
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Thus the work in this thesis offers strong evidence that the ACE  gene modifies risk of 
CHD and T2D in the presence of known risk factors.
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References
Chapter 1: Introduction
Renin Angiotensin System (RAS)
Renin was first identified by Tigerstedt and Bergman at the end of the 19th Century. It 
was subsequently shown to be a protease, converting the a : globulin, angiotensinogen to 
the decapeptide, angiotensin I (Ang I). The function of endocrine RAS was initially 
thought to be only maintenance of cardiovascular homeostasis. It has since become 
clear that local tissue RAS also exist, where they have paracrine, autocrine and 
intracellular roles. Circulating ACE contributes less than 10% of total body ACE, with 
the largest proportion of ACE located in tissue compartments (Cushman and Cheung, 
1971). RAS components have been found in various tissues including cardiac (Danser,
1996), vascular endothelium (Dzau, 1993), brain (Hilbers et al., 1999), lung (Pieruzzi et 
al., 1995), kidney (Harris and Cheng, 1996), adipose tissue (Schling et al., 1999), 
pancreas (Semia, 2001) and skeletal muscle (Reneland and Lithell, 1994).
Angiotensin I Converting Enzyme (ACE) (158 kDa) plays a key role in the RAS 
through acting as a dipeptidyl carboxypeptidase. By removing the C-terminal dipeptide, 
it converts Ang I (decapeptide) to Ang II (octapeptide) and inactivates bradykinin (BK). 
ACE can exist in two forms: a somatic form containing two homologous zinc-binding 
catalytic domains, and a truncated testicular form containing only the C-terminal 
catalytic domain necessary for fertility. ACE is anchored to the plasma membrane of 
endothelial or epithelial cells by its C-terminus, which is subsequently cleaved by ACE 
secretase to yield circulating ACE (Wei et al., 1991). The complexity of RAS has 
increased through the discovery of ACE2 (homologue of ACE) which converts Ang I to
12
inactive Ang(l-9) and converts Ang II to vasodilator Ang(l-7) (Vickers et al., 2002). 
Figure 1.1 is a diagram outlining the RAS.
Figure 1.1 (from (Schmieder et al., 2007))
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Ang II acts via at least two different types o f G-protein-coupled receptors -  the Ang II 
type 1 (AT]R) and type 2 (AT2R) receptors. The systemic function of the RAS acting 
via AT|R is to maintain cardiovascular homeostasis. It is activated by the sympathetic 
nervous system, volume loss and salt loss. Persistent activation of RAS however causes 
oxidative stress, inflammation, hypertrophy and fibrosis affecting vascular smooth 
muscle cells, endothelial cells, cardiac myocytes and the extracellular matrix (reviewed 
in (Mehta and Griendling, 2007)). As well as affecting the cardiovascular system, the 
presence of local RAS can cause fibrosis in lung (Marshall et al., 2000) and kidney 
(Mezzano et al., 2001), and inflammation in adipose tissue (Engeli et al., 2000). The 
AT2R is thought to oppose the actions o f the AT]R (Matsubara, 1998). The detrimental 
role of ACE in cardiovascular disease is highlighted by the evidence that ACE
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inhibitors have been shown to improve morbidity and mortality in cardiovascular 
disease and heart failure (Y usuf et al., 2000; SOLVD Investigators, 1991).
The RAS is intimately connected to the Kallikrein-Kinin system. Bradykinin 
(inactivated by ACE) act upon Pi and P: G-protein coupled cell-surface receptors 
(termed BDKRB1 and BDK.RB2, respectively). Kinins cause vasodilatation (via nitric 
oxide and prostaglandin release) and are thought to be protective against atherosclerosis 
(Su et al., 2000), and left ventricular hypertrophy (LVH) and heart failure (Liu et al.,
1997). Reduced kinin degradation may therefore contribute to the beneficial effects of 
ACE inhibition (Linz et al., 1995).
AC E  (I/D) polymorphism
The ACE  gene (Figure 1.2) located on the long arm o f chromosome 17 (17q23), is 21 kb 
long and contains 26 exons (Sayed-Tabatabaei et al., 2006). The human ACE  gene has 
close homology with a wide range o f other species, and its structure may be the result o f 
gene duplication (Hubert et al., 1991). The NCBI database lists more than 160 
polymorphisms, the majority being single nucleotide polymorphisms (SNP). 34 are in 
coding regions o f which 18 lead to missense mutations (Sayed-Tabatabaei et al., 2006). 
Transcription o f testicular ACE mRNA differs from the somatic ACE mRNA in that 
somatic form is transcribed from the prom oter on the 5' end (leading to transcription o f 
all exons) and the testicular form is transcribed from an internal promoter in intron 12 
(Howard et al., 1990).
ACE levels are under considerable variation between individuals, with evidence o f 
strong heritability (Cambien et al., 1988). In 1990 a common variant in AC E  (Figure
14
1.2) - the insertion (I) or deletion (D) of a 287 bp fragment (Alu repeat) in intron 16 was 
shown to be associated with differing serum and tissue ACE activity, with the insertion 
associated with lower levels (Rigat.B. et al., 1990). Studies have demonstrated that the 
polymorphism is responsible for 18% to 47% of variance of tissue and plasma ACE 
levels in western Caucasian populations (Danser et al., 1995; Costerousse et al., 1993; 
Rigat.B. et al., 1990). This association is ethnic specific, being replicated in Japanese 
(Yamamoto et al., 1997) and Mexican American cohorts (Kammerer et al., 2004) but 
with more modest effects reported in black cohorts (Forrester et al., 1997; Cox et al.,
2002). In non-black populations, the ACE  (I/D) polymorphism is most probably in 
strong linkage disequilibrium (LD -  term explained later) with a functional 
polymorphism directly responsible for genetic variation of ACE levels.
There has been an intensive work to find the functional polymorphism. The presence of 
two possible ACE determining quantative trait loci has been suggested with one being 
in strong LD with the 1/D polymorphism and the other in the 5’ region (Villard et al., 
1996). In view of the close LD operating over the chromosomal region where the gene 
is located, ACE activity has been associated with a small number of haplotypes that 
exist within the gene (Keavney et al., 1998). Despite all the efforts, the precise 
functional polymorphism is yet to be determined. It is most likely in the region between 
intron 18 and 3 ’UTR (Zhu et al., 2000) however there remains evidence for a 
contribution from 5’UTR region (Villard et al., 1996) and possibly a trans element on 
chromosome 4 (Kammerer et al., 2004). Regardless, in Caucasians, ACE{\JD) 
polymorphism is in strong LD with the majority o f polymorphisms in the putative 
region (Payne et al., 2007) and remains a useful marker of ACE levels, and therefore 
can be used as a genetic tool to explore disease processes in which RAS has been
15
implicated. Angll levels have not been used in evaluating the ACE(\1\))  polymorphism 
in view of the difficulties o f measuring it.
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Figure 1.2 Schematic Representation o f ACE  (not to scale), with reference to I/D 
polymorphism and a LD plot demonstrating the strong LD within the gene. Darker 
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Coronary Heart Disease
Cardiovascular disease (CVD) remains the largest cause of death in the industrialised 
world, with increasing prevalence in developing countries adopting western lifestyles 
(Zipes and Libby P et al, 2005). In the UK it is responsible for more than 200,000 
deaths a year, and coronary heart disease (CHD) -  itself the largest cause of death, 
causes more than 100,000 deaths a year (BHF, 2007). Death rates from CVD (and 
CHD) have been decreasing every year since the 1970s, however in view of the increase 
in longevity of the population, disease prevalence is probably increasing (BHF, 2007). 
Coronary Heart Disease (CHD) is a progressive inflammatory disorder involving 
endothelial dysfunction, dysregulated lipoprotein metabolism and coagulation which is 
instigated through an interaction o f genetic and environmental risk factors. The 
principal modifiable risk factors are cigarette smoking, hypertension, type 2 diabetes 
and dyslipidaemia. Non-modifiable risk factors include age, gender and family history.
Numerous studies have demonstrated that family history of CHD is an important 
vascular risk factor (Goldbourt and Neufeld, 1986). Most premature CV events occur in 
families where there is a positive family history o f CHD (Pohjola-Sintonen et al., 1998). 
A substantial proportion of this influence is due to the inheritance of the classical risk 
traits for CHD as demonstrated in twin studies (Feinleib et al., 1977; Austin et al.,
1987). However, family history is a strong independent risk factor for CHD itself 
(Lloyd-Jones et al., 2004) (Hawe et al., 2003) demonstrating that there are unmeasured 
genetic risk factors as well. Supporting this is the fact that the Framingham algorithm 
cannot explain approximately 1 in 5 CHD events using ‘conventional’ risk factors 
(Cooper et al., 2005). Genes involved in ‘novel’ risk factors (e.g. CRP, IL6 and 
fibrinogen), working through CHD mechanisms such as inflammation and innate
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immunity, may be responsible for family history of CHD. Though now there is less 
consensus for CRP and inflammatory markers being independent CHD risk factors 
(Casas et al., 2006b), so genes in alternative plausible pathways such as cell senescence 
or those yet to be discovered may be the cause for family history being an independent 
risk factor.
Gene-association studies in CHD
One powerful way to identify culprit genes in complex diseases like CHD is through 
knowledge o f the underlying biological pathways that underpin the disease. Specific 
genes that are known to code for enzymes or structural proteins that are in these 
pathways (which lead to the formation of causal traits e.g elevated cholesterol or higher 
blood pressure or a pro-inflammatory state) are therefore ideal ‘candidate genes’. 
Common variants within these genes which are associated with a change in function of 
protein or altered trait level can then be typed (using standard molecular techniques) in a 
cohort of cases and controls. If the frequencies differ statistically significantly between 
these two groups then the variant is associated with the phenotype in question.
Over the last 20 years there have been vast numbers of gene association studies -  over 
3500 in CHD alone (Casas et al., 2006a). Though many have reported a positive 
association between genotype and phenotype, only a minority of these associations have 
been consistently replicated. There are several reasons for this (reviewed in (Hirschhom 
et al., 2002) and (Colhoun et al., 2003) - a common one being that the underlying 
genetic effect is mild to modest at most, therefore if the cohort is small to medium 
sized, it may be underpowered to detect an effect with a high degree o f statistical
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certainty. Frequently the initial positive study also overestimates the initial effect (the 
so-called ‘winners curse’), therefore subsequent studies need even more subjects for 
confirmation of a significant result.
Another reason why initial results may be a false positive is because of the publication 
bias that exists toward positive association studies, and those which refute associations 
tend not to be published. A further problem is that some study designs include subjects 
from different ethnicities; this can introduce error because both the allele and phenotype 
in question may vary in frequency or prevalence by ethnicity.
In a substantial proportion of cases, the candidate polymorphism genotyped is not itself 
functional but is in LD with the functional polymorphism. LD or allelic association, is a 
population-based concept describing a situation in which a certain allele at one locus 
occurs in the presence of a specific allele at a second locus more frequently than 
expected by chance alone. Thus the candidate variant can act as a marker for the 
functional variant. It is usually measured as D ’ ranging from 0 -  no association between 
the variants to 1 -  100% segregation of both variants together. Therefore errors can be 
introduced if the candidate variant is not in strong LD with the functional variant, or if 
there is ethnic admixture where the LD between candidate and functional variant 
changes.
Complex diseases are the product of several genes and environmental factors interacting 
together and therefore an observed gene association study which is a consequence of 
interaction with the genetic milieu and environmental setting of the particular cohort, 
will only have a reduced chance of replication in another cohort unless the studies are 
exactly similar. A related problem is that in seeking these interactions, multiple testing
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increases the likelihood of false-positives. Individual SNP association studies also do 
not capture the full variation across the gene in interest. Tagging SNPs that combine 
SNPs from those that are in close LD is one method of accomplishing this (Wootton et 
al., 2006) however there are specific disadvantages with this, including reliance of 
strong LD across specified region, that the phenotype should be determined by many 
common genetic variants (and not rare ones), and the subsequent determination of 
functionality from the positively associated SNPs.
From these criticisms have come guidance for doing gene association studies -  ideally 
they should be very large (in the order o f more than a thousand subjects) in order to pick 
up mild effects when the rare allele frequency is in the order of at least 10% (Casas et 
al., 2006a). Another important suggestion is that meta-analysis should be used to pool 
the results of association studies (thereby increasing the power) in order to demonstrate 
mild to moderate effects with good statistical power. Meta-analyses that include from 
upwards of 2800 subjects have demonstrated CHD risk effects of 11 genotypes with a 
magnitude between 1.1 to 1.3 (Casas et al., 2006a). An important criticism of meta­
analyses is that they continue the problem of positive publication bias but the pooling of 
only large studies is a substantial advantage. To reduce problems from ethnic admixture 
and confounding from differing gene-environment and gene-gene interactions the 
cohort should ideally be homogeneous with the same ethnicity and same gender.
Most studies are cross-sectional which are easier to perform and have the advantage of 
recruiting large numbers of cases as well as controls. Prospective gene association 
studies have several advantages in preventing confounding from survivor bias and 
retrospective patient recall o f lifestyle factors. Through also enabling environmental 
factors to be measured at baseline, important gene-environment interactions can be
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explored. Problems with this type of study include the cost and logistics of follow-up, 
together with the need for even larger numbers and substantial follow up required to 
achieve statistically significant associations in view of event rate in diseases like CHD 
being relatively low (Casas et al., 2006a).
Gene environment interaction (GEI)
Gene environment interactions is a concept that is being increasingly used to examine 
and explain the effect of plausible disease causing or disease modifying genes. In the 
presence o f a harmful stimulus e.g smoking or hypertension a gene variant (or its 
product) would increase the risk o f disease e.g CHD however in the absence of this 
stimulus, possession of the gene variant leads to no increased risk of disease. 
Alternatively the disease risk comparison between the two alleles /genotypes varies by 
the presence of the stimulus. This is biologically conceivable in that pervasive 
environmental factors like smoking and hypertension switch on (or modify) different 
genes (or gene clusters) at a transcriptional or at a translational level altering function at 
a cellular and tissue level (Spira et al., 2004)(Grayson et al., 2007). In view of the 
complexity o f polyphenotypes involving interactions between several risk ‘genes’ and 
several environmental risk ‘factors’, it is convenient to envisage a scenario when an 
individual with a higher ‘genetic’ risk enters a high risk environment, leading to a 
substantially increased disease risk (Figure 1.3).
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Figure 1.3 (from (Talmud, 2007))
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Examples of Gene environment interaction (GEI) on CHD risk
In view of the difficulty o f determining GEI (as explained above), so far only a small 
number of such associations has been found for CHD. Several have been determined in 
the Northwick Park Heart Study2 (NPHS2) which is a prospective study of 3052 
healthy middle aged men followed since 1990 looking at development of CHD (Miller 
et al., 1995). Examples which have been found so far using this study have been 
included in Table 1.1.
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Table 1.1 Results of gene environment interaction studies on CHD in NPHS-II (adapted from Casas 2006)
Gene V ariant1
Genetic model M ain genetic 
R R
(95% CI)
Main R R  (95% CI) 
o f sm oking or 
hypertension
R R  (95% CI) in 
sm okers or 
hypertensives with 
risk genotype4
C andidate System Reference
Smoking
LPL D9N
N9 vs D9 2.33 (1.08-5.03) 1 .8 9 (1 .2 8 -2 .7 9 ) ' 10.38(4.72-22.81) Lipid levels. Plaque foam cell 
developm ent
(Talmud et al., 2000)
A P O E E3/E2/E4 E4 vs E3 0.82 (0.59-1.15) 1.73 (1.10-2.73)2 2 .7 9 (1 .5 9 -4 .9 1 ) Levels o f  atherogenic lipoprotein (Humphries et al., 2001)
MMP3 5A>6A
6A vs 5A 1.91 (1.11-3.28) 1.99 (1 .3 0 - 3 .0 6 ) 2 4.01 (1.57-10.24) Plaque matrix deposition and plaque 
receptor
(Humphries et al., 2002)
PE C  A M R670G RR vs GG 1.07 (0.75-1.94) 1.65 (1.15-2.35)“ 2 .1 6 (1 .1 6 -4 .0 1 ) M onocyte ingress into plaque (Elraycss et al., 2004)
Hypertension
AG T2R 1657A>G A vs G 1.0 (0 .7 5 -1 .3 4 ) 2.08 (1 .5 1-2.88)J 2.30 (1 .4 9 -3 .5 5 ) Inflam m ation and vascular function + (Jones et al., 2003)
BDKRB1 -699G>C GG vs CC+GC 1.0 (0.66-1.51) 2 .04(1 .44-2 .89)3 1.88(1.11 -3 .19 ) Cardiac growth in response to (Dhamrait et al., 2003)
BDKRB2 +9/-9bp +9+9 vs -9-9 0.75 (0.32-1.75) 1.68 (0.86-3.29)3 2.21 (0.86-5.70) hypertension (Dhamrait et al., 2003)
LPL S447X SX+XX vs SS 1.06(0.76-1.48) 1.35 (1 .19-1 .53)3 1.83 (1.20-2.77) Lipid levels. Substrate delivery (Talmud et al., 2007)
1: Risk allele shown in bold. 2: Relative risk o f  sm oking on CHD. 3: Relative risk o f  hypertension on CHD. 4: Relative risk o f  CHD in subjects carrying the candidate gene-variant 
and the environm ental risk factor (sm oking or hypertension) com pared with subject who do not carry the gene-variant and the environm ental risk factor
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Gene-smoking interaction on CHD risk
Table 1.1 demonstrates that smoking interacts with genes involved in lipoprotein 
metabolism, and vascular remodelling. This reflects the varied pro-atherosclerotic 
processes affected by smoking: endothelial dysfunction (Blann, 1992), up-regulation of 
adhesion molecules necessary for monocyte and platelet attachment (Lu and Creager,
2004); impact on lipid metabolism with reduced HDL and increased LDL and 
triglycerides (Eliasson et al., 1997). Interestingly the effect of the LPL D9N interaction 
was independent of its effect on triglycerides, but this association has not been 
examined in any studies. The APOE-smoking interaction (Humphries et al., 2001) has 
been most studied with subsequent replication in the Framingham Offspring study 
(Talmud et al., 2005).
Gene-hypertension interaction on CHD risk
Essential hypertension, a complex phenotype itself resulting from multiple gene- 
environmental interactions, exerts an effect on a wide range of tissues including the 
kidney, heart, vascular tree and brain. It is an independent cause of CVD (including 
CHD and stroke) and renal failure, and is strongly associated with the development of 
left ventricular hypertrophy (LVH) and heart failure (Chobanian et al., 2003) (Levy et 
al., 1988).
There is a continuous and linear association between both systolic and diastolic blood 
pressure and CHD and stroke mortality which exists down to ‘normal’ blood pressures 
from 115/75mmHg (Prospective Studies Collaboration, 2002). This is illustrated for 
CHD in Figure 1.4.
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Figure 1.4: Ischaemic heart disease (IHD) mortality rate in each decade of age versus 
usual blood pressure at the start o f that decade (Prospective Studies Collaboration, 
2002).
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Key pathophysiological abnormalities in hypertension include inappropriate regulation 
of extracellular osmolality (and volume) mediated by the kidneys (Guyton, 1990) and 
the presence o f generalised membrane abnormalities (Orlov et al., 1999). Altered 
sodium handling (Guyton, 1990), compounded by sympathetic nervous system and 
RAS activation lead to sodium and fluid retention and promote the development of 
hypertension (Mark, 1996; McConnaughey et al., 1999). Increased peripheral arterial 
resistance due to vascular remodelling, a hallmark of hypertension causes an 
impairment o f autoregulation (or control of tissue perfusion) which is important in the 
development o f target organ damage (Mulvany, 1999).
Given the spectrum of tissues affected by hypertension with the presence o f systemic 
abnormalities, it is very likely that gene expression is changed (causing changes in
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harmful enzyme or receptor activity) and GEI is thus possible in predisposing certain 
individuals or groups to a greater CHD risk. From table 1.1, gene variants involved in 
lipid metabolism and RAS combine with blood pressure to raise CHD risk. It is 
conceivable that lipoprotein metabolism genes interact with hypertension in view of the 
clustering of hypertension and dyslipidaemia in the metabolic syndrome (Eckel et a l . ,). 
Genes involved in RAS are particularly ideal candidates to modify the detrimental 
effects of hypertension as the RAS is heavily implicated in the development of 
hypertension (McConnaughey et al., 1999) and many of its components are present in 
tissues where end organ damage occurs.
Role of ACE  (I/D) polymorphism in CHD
Cambien initially reported an association o f the D allele with risk of myocardial 
infarction (MI) (Cambien et al., 1992). Since then many small studies have confirmed 
the D allele and DD genotype MI risk but large scale cohort studies have shown no 
significant association (Keavney B. et al., 2000). A meta-analysis looking at the ACE 
polymorphism concluded that the risk of MI associated with carrying the DD genotype 
was 1.22 [95% Cl 1.11 -1.35] (Morgan et al., 2003) as illustrated in Figure 1.5.
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Figure 1.5: Impact of sample size on random effects odds ratios (OR) for myocardial 
infarction (MI) (ACE DD genotype vs II or ID). Cl (confidence interval) (Morgan et al.,
2003)
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Emerging evidence for ^C£(I/D) polymorphism as a modifier in CHD
Since the advent of large prospective gene association studies, the ACE  gene has been 
shown to alter the development of polyphenotypes (e.g. CHD, CVD, hypertension) 
through interaction with other stimuli such as smoking, age and blood pressure (Sayed- 
Tabatabaei F.A. et al., 2005). Interaction between smoking and the ACE  polymorphism, 
has been implicated in an increase in CHD mortality (Sayed-Tabatabaei F.A. et al.,
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2005), and an increase in risk of hypertension both in younger age groups (Schut et al., 
2004a). An interaction between the ACE D allele and hypertension has been found to 
lead to an increase in risk of heart failure (Schut et al., 2004b).
Influence of variation in the ACE gene on CHD is highly plausible in that RAS is 
expressed in the vascular endothelium and myocardium, and that Ang II can play an 
important role in driving atherosclerosis (Harrison et al., 2003; Ferrario and Strawn,
2006) and cardiac hypertrophy (Li et al., 2002; Wenzel et al., 2001). The impact of 
specific CHD risk factors namely hypertension and lipids on ACE (and other RAS 
components) have been described:
Hypertension:
Hypertension and RAS are strongly linked. Activation of RAS may precede the others 
development but it is likely they potentiate each other. There is overwhelming evidence 
from animal models that Angll is involved in vascular remodelling that is central to the 
vascular damage in hypertension. In large artery remodelling, Angll induces smooth 
muscle cell hypertrophy, collagen deposition, endothelial dysfunction and cytokine 
secretion (Albaladejo et al., 1994; Kakar and Lip, 2007). In small artery remodelling, 
RAS is clearly involved with Angll induced changes mediated by MAPKs and ROS 
generation via activation of NADPH (Touyz et al., 2002; Virdis et al., 2004).
RAS is heavily implicated in the development of atherosclerosis specifically with ACE 
expressed in foam cells and lymphocytes o f human carotid atherosclerostic lesions 
(Fukuhara et al., 2000). Through animal models of atherosclerosis for the most part, 
Angll has been shown to cause endothelial ROS production with subsequent endothelial 
dysfunction (Wang et al., 2001; Anderson et al., 2000), SMC hyperplasia (Daemen et
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al., 1991), matrix deposition (Castoldi et al., 2003), and increased vascular permeability 
(Tamarat et al., 2002). Greater ACE activity has been demonstrated from coronary 
lesions of patients with acute coronary syndromes compared to lesion from patients 
with stable CHD suggesting that RAS is associated with a more vulnerable plaque 
(Hoshida et al., 2001).
It is therefore very clear to see why, in individuals who have greater plasma and tissue 
levels of ACE (i.e. those that carry the D allele of 1/D polymorphism), hypertension will 
affect susceptible tissues to a greater extent, thereby raising CHD risk. RAS also plays 
an important role in cardiac hypertrophy through cardiomyocyte hypertrophy (Li et al., 
2002) and myofibroblast remodelling affecting interaction with the extracellular matrix 
(Siwik et al., 2001). Furthermore, the ACE  D-allele is associated with a greater left 
ventricular (LV) growth response to a variety of stimuli (Estacio et al., 1999; 
Montgomery et al., 1997; Lechin et al., 1995) including hypertension (Iwai et al., 1994), 
and given that exuberant LV growth is independently associated with excess CHD risk 
(Levy et al., 1988; Haider et al., 1998), an interaction o f ACE  with hypertension in 
determining CHD risk would appear entirely logical. ACE inhibitors reduce CHD 
events (Yusuf et al., 2000; Fox et al., 2003) in high risk individuals through reducing 
blood pressure but also through other putative anti-atherosclerotic mechanisms. This 
also supports evidence for raised ACE (and RAS) levels being pathogenetic in 
hypertension but also having further impact on CHD mechanisms and surrogates 
including atherosclerosis and LVH.
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Lipids:
Lipids play a central role in the development of atherosclerosis and are an independent 
risk factor for CHD (Wilson et al., 1998). Their deposition in the arterial endothelium 
enables the expression of adhesion molecules such as PECAM 1 and ICAM 1 which 
promote the sticking and transmigration of leucocytes into the arterial wall (Frostegard 
et al., 1991; Ross, 1999). The trapped LDL undergoes further modification including 
oxidation which perpetuates the inflammatory process by causing macrophages to 
become foam cells (Lusis, 2000).
There is evidence that hypercholesterolaemia increases plasma Angll concentrations 
(Daugherty et al., 2004). Angll is also involved in LDL oxidation and uptake (Keidar et 
al., 2001). It has therefore been suggested that there is a positive feedback relationship 
with high cholesterol levels increasing Angll and Angll increasing lipid uptake (Keidar 
et al., 2001). It is therefore plausible that there may be a positive interaction between 
elevated lipid status and ACE  I/D polymorphism on CHD risk. Interestingly, Cambien 
et al (Cambien et al., 1992) initially reported an ACE  genotype DD interaction with 
plasma ApoB levels and BMI, finding a risk ratio of 3.2 with low ApoB (< 1.25g/L) and 
low BMI (< 26kg/m2). This was difficult to explain biologically and has not been 
confirmed by others (Keavney B. et al., 2000).
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Figure 1.6: Diagram of atheromatous plaque formation (Zipes and Libby P et al, 2005)
Circulating monocyte, 
adhesion then migration
Foam cell
Smooth m uscle cell 
proliferation
Lipoprotein uptake via 
scavenger receptors
Therefore ACE{I/D) polymorphism is an excellent candidate modifier gene to study in 
CHD in view of the wide distribution of ACE in culprit tissues and its key role in 
disease development especially in the presence of known risk factors.
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Type 2 Diabetes
Type 2 Diabetes (T2D) is a huge and increasing burden on morbidity and mortality 
throughout the world. The worldwide prevalence was estimated to be 2.8% in 2000 
(Wild et al., 2004) but in view of changes in lifestyle and diet, and particularly a rise in 
obesity, the number of people with diabetes will double between 2000 and 2030 (Wild 
et al., 2004).
Figure 1.7: Estimated global number o f adults with diabetes by age-group in 2000 and 
2030 (Wild et al., 2004)
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In the UK there are currently over 2 million people with diabetes (Diabetes UK, 2006). 
Patients with T2D have a 2-4 fold higher incidence of CHD (Garcia et al., 1974). There 
is also a higher risk of stroke, amputation, kidney disease and blindness (Klein, 1995). 
The pathogenesis of T2D is due to impaired insulin action or insulin resistance and 
impaired insulin secretion (which occurs later). T2D and CHD are thought to be closely 
linked with shared aetiological mechanisms including inflammation (Pradhan and 
Ridker, 2002). The clustering of components of the metabolic syndrome including 
obesity, dyslipidaemia, hypertension and insulin resistance underlie both diseases 
(Pradhan and Ridker, 2002; Haffner, 2002).
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There is also a substantial genetic component to T2D as evidenced by family studies 
(Meigs et al., 2000), twin studies (Barroso, 2005) and variation in frequency between 
ethnic groups (Simmons et al., 1991). As in polyphenotypes like CHD, T2D is probably 
conferred by a number of genes each with modest effect, interacting with their 
environment. Again like CHD there have only been a small number of SNPs so far that 
have demonstrated a consistent T2D risk effect confirmed by meta-analyses (reviewed 
in (Gable et al., 2007a)). Though no meta-analysis has as yet been published, the 
TCF7L2 intronic gene variants have consistently been shown to influence T2D ‘risk’ 
with an odds ratio of 1.4 for heterozygote and 1.8 for homozygote risk allele 
(Humphries S.E. et al., 2006), with a high population-attributable fraction of 
approximately 20% (Humphries S.E. et al., 2006; Groves et al., 2006).
GEI in T2D
In terms of GEI, data has been understandably limited in view of the difficulty 
evaluating these relationships. Obesity is the most likely environmental factor to be 
studied in view of it being the single most important risk factor for T2D (Gable et al., 
2006). Obese individuals have a greater CHD risk (Lamarche, 1998), and there is 
evidence that adipose tissue (especially when located centrally) is pro-inflammatory, 
secreting tumour necrosis factor-alpha and Interleukin-6 (IL-6) (Kern et al., 1995; Fried 
et al., 1998) thereby actively worsening insulin resistance and increasing T2D risk.
An interaction between PPARG Pro 12Ala and obesity on T2D risk has been determined 
with the Ala allele conferring protection only in those individuals with lower body mass 
index (under 34 kg/m2) (Florez et al., 2007a). An interaction between a nonsynonymous
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polymorphism in APM, (+276G>T) and obesity on T2D risk has been demonstrated 
with an increased risk associated with +276T carriers in the obese men but not in the 
lean men (Gable et al., 2007b). An interaction between lifestyle intervention and 
TCF7L2 rs7903146(C>T) on T2D risk has also been reported but was not statistically 
significant (Florez et al., 2006).
In view o f T2D being an arbitrary definition for a state o f glucose intolerance (or insulin 
resistance), interactions have been sought with insulin resistance and other T2D 
surrogates e.g K C N Jll  E23K SNP has been shown to effect insulin secretion in patients 
with impaired glucose tolerance (Florez et al., 2007b).
Role of ACE  (1/D) polymorphism in T2D
There is good evidence that RAS plays a role in the pathogenesis o f T2D. They exist in 
tissues controlling glucose metabolism i.e adipose tissue, skeletal muscle and pancreas 
(Karlsson et al., 1998). Ang II is also diabetogenic through a number o f mechanisms, 
including interfering with insulin signalling, having a pro-inflammatory effect on tissue 
beds causing endothelial dysfunction, inhibiting adipocyte differentiation, and causing 
beta cell dysfunction via oxidative stress (Hattori et al., 2005; Leung and Carlsson,
2005; Engeli et al., 2003). A meta-analysis has shown ACE-inhibitors or Angiotensin II 
Receptor blockers (ARB) can delay the development o f T2D in high-risk individuals 
(Scheen, 2004).
The ACE  I/D polymorphism has been widely studied on T2D risk with varying results. 
The D allele has been associated with a higher T2D risk [OR=1.52,p=0.02] in a case-
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control study (Stephens et al., 2005). In those with T2D, D allele carriers have poorer 
outcomes, with a higher risk o f myocardial infarction and renal disease (Kennon et al., 
1999), and a worse response when starting on an intensive hypoglycaemic medication 
regime (Salonen et al., 2006). Paradoxically the D allele has been associated with a 
higher insulin sensitivity (Panahloo et al., 1995). Combined SNP interactions or 
haplotype effects have been reported in diabetic nephropathy (Osawa et al., 2007; Ng et 
al., 2006), and there is a consistent observation o f the D allele being specifically 
associated with diabetic nephropathy (Sayed-Tabatabaei et al., 2006). There is however 
no consensus between this genotype and T2D risk with negative studies published 
(Grammer et al., 2006; Schmidt and Ritz, 1997). Despite this, the role o f RAS in T2D 
pathogenesis in several areas, and the observation that ACE inhibition may decrease 
T2D risk (Scheen, 2004) lends weight to an effect o f the ACE  I/D polymorphism, and 
therefore robust consideration o f GEI should be taken into account. Obesity is the most 
powerful T2D risk factor and its strong inflammatory component complements RAS 
activation and therefore it is plausible that there is an interaction between obesity and 
ACE  (I/D) polymorphism.
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Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is a common genetic heart muscle disorder, 
inherited in an autosomal dominant manner, characterised by unexplained left 
ventricular hypertrophy, with a prevalence in the order of 1 in 500 (Maron et al., 1995). 
The clinical course is highly variable, ranging from asymptomatic throughout life to 
premature sudden death, heart failure and arrhythmia. It is the most common cause of 
sudden death in young adults (Maron et al., 1995). Histological features include 
myocardial disarray and fibrosis. The initial pathogenetic insult in the myocardium is 
ascribed to a cellular energetic deficit (Ashrafian et al., 2003).
Figure 1.8: Histological specimen and Magnetic Resonance Image of Hypertrophic 
Cardiomyopathy
There is an overall tendency in HCM for gradual wall thinning and a gradual decrease 
in systolic performance over time (Thaman et al., 2004; Thaman et al., 2005). Survival 
rates have however improved over the last 40 years and recent studies demonstrate an 
annual mortality rate of less than 3%, annual sudden death rate (most common mode of 
death) of 1% and annual heart failure death (or cardiac transplantation) rate of 0.5% 
(Elliott et al., 2006). Despite this there are individuals and families who however have
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malignant phenotypes with high rates o f  sudden death, heart failure and stroke (Elliott et 
al., 2000; Thaman et al., 2005; Kubo et al., 2007).
The first causative mutation, discovered in 1989 occurred in cardiac Beta-myosin heavy 
chain gene, a sarcomeric protein gene (Geisterfer-Lowrance et al., 1990). The majority 
o f mutations have since been found in sarcomeric protein genes, the commonest being 
in genes coding for Beta-myosin heavy chain, Myosin binding protein C and Troponin 
T (Marian, 2002). The remaining causative mutations are in other sarcomeric protein 
genes, AMP kinase gene (Blair et al., 2001b), mitochondrial DNA (Simon and Johns, 
1999) and also occur in triplet repeat syndromes (Phillips and Harper, 1997). Not all 
disease-causing mutations have been discovered, with screening only detecting 
mutations in up to 70% o f patient cohorts (Ashrafian and Watkins, 2007). HCM not 
only exhibits genetic heterogeneity as described above, but exhibits allelic heterogeneity 
with many mutations found in each gene -  at least 70 identified in Beta-myosin heavy 
chain, more than 40 in Myosin binding protein C, and at least 15 in Troponin T 
(Marian, 2002). The frequency o f each causal mutation is low, with many o f the 
mutations not being found elsewhere (Marian, 2001).
Studies have suggested that HCM caused by beta myosin heavy chain mutations cause 
early onset disease with greater LVH and a higher sudden death rate compared to HCM 
caused by myosin binding protein C gene mutations (Abchee and Marian, 1997;
Charron et al., 1998). Troponin T mutations have been associated with mild LVH but 
with a high incidence o f sudden death (W atkins et al., 1995). Despite this, many studies 
have demonstrated that though some mutations are associated with specific phenotypes, 
the phenotypes are not gene specific with some mutations conferring no association 
with phenotype (Ackerman et al., 2005; Watkins et al., 1992; Watkins et al., 1995).
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Figure 1.9 demonstrates the substantial differences in mortality between HCM patients 
with different Beta-myosin heavy chain and Troponin T mutations. Furthermore even 
within affected families (with identical mutations) there is definite phenotypic variance 
(Ashrafian and Watkins, 2007). One reason may be the inheritance of compound 
mutations may be more common than expected (Blair et al., 2001a). Another 
explanation for this could be presence of other modifier genes e.g in hypertrophic or 
fibrotic response, or environmental factors e.g hypertension, which interact with the 
causative gene to influences the phenotype.
Figure 1.9: Kaplan-Meier survival curves in patients with HCM associated with 
different Beta-myosin heavy chain and Troponin T mutations demonstrating marked 
variation in mortality (Watkins et al., 1995)
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Modifier genes in HCM
Searching for ‘modifier’ genes has so far been limited. Using the candidate gene 
association study approach, results have been conflicting. Polymorphisms in the RAS 
have been most widely studied since they are ideal contenders -  being localised in the 
myocardium (Danser, 1996), with Angll inducing cardiomyocyte hypertrophy (Sabri et 
al., 1998) and myofibroblast remodelling (Siwik et al., 2001). In terms of the ^C£(I/D) 
polymorphism, the D-allele is associated with a greater left ventricular (LV) growth 
response to a variety of stimuli (Lechin et al., 1995)(Estacio et al., 1999)(Montgomery 
et al., 1997) including hypertension (Iwai et al., 1994). Specifically with regard to 
HCM, the DD genotype has been associated with higher risk of sudden death (Marian et 
al., 1993) and increased severity of hypertrophy (Lechin et al., 1995; Tesson et al., 
1997), accounting for 10-15% of variability of hypertrophy (Lechin et al., 1995). Other 
studies have demonstrated no association between this polymorphism and HCM 
(Yamada et al., 1997; Osterop et al., 1998). Other SNPs in the RAS -^G T M 2 3 5 T  and 
AGTR 1166 A/C have been studied in HCM with mixed results (Ishanov et al., 1997; 
Brugada et al., 1997; Osterop et al., 1998). SNPs in endothelin 1 and TNF alpha genes 
have also been associated with severity of hypertrophy in HCM (Brugada et al., 1997; 
Patel et al., 2000). Results of gene association studies have been summarised in Table 
1.2. The varied results are not surprising in view of typical problems associated with 
such studies including limited sample size and cross-sectional heterogenous cohorts.
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Table 1.2 Summary o f ‘modifier gene’ association studies in HCM (from (Marian, 
2002))
Gene Polym orphism Association with HCM 
phenotype
Reference
Angiotensin converting 
enzyme
I/D DD genotype associated 
with higher risk o f  SCD 
DD genotype associated 
with severity o f 
hypertrophy 
No genotype 
association with 
hypertrophy 
DD genotype more 
com mon in HCM 
Genotype frequency 
unchanged
(Marian et al., 1993)
(Lechin et al., 1995; 
Tesson et al., 1997)
(Yamada et al., 1997; 
Osterop et al., 1998)
(Pfeufer et al., 1996; 
Yoneya et al., 1995) 
(Yamada et al., 1997)
Angiotensinogen M 235T , T174M  
-6 G/A
235T allele more 
common in HCM 
Genotype frequency 
unchanged 
No genotype 
association with 
hypertrophy
(Ishanov et al., 1997) 
(Yamada et al., 1997)
(Brugada et al., 1997; 
Yamada et al., 1997)
Angiotensin II 
receptor 1
1166 A/C C allele associated with 
severity o f  hypertrophy 
No genotype 
association with 
hypertrophy
(Osterop et al., 1998) 
(Brugada et al., 1997)
Bradykinin B2 receptor T21M M allele found in HCM 
cases but not in controls
(Erdmann et al., 1998)
Aldosterone Synthase -344 T/C No genotype 
association with 
hypertrophy
(Patel et al., 2000)
Endothelin-1 8002G/A A allele associated with 
severity o f  hypertrophy
(Brugada et al., 1997)
Tum or necrosis factor a -308G/A A allele associated with 
severity o f  hypertrophy
(Patel et al., 2000)
Platelet activating factor 
A cetylhydrolase
994G/T T allele more common 
in HCM and associated 
w ith increased left 
ventricular dimension 
and decreased function
(Yamada et al., 2001)
Insulin-like growth 
factor 2
820G/A No genotype 
association with 
hypertrophy
(Patel et al., 2000)
Transform ing growth 
factor B 1
-509C/T No genotype 
association with 
hypertrophy
(Patel et al., 2000)
Interleukin 6 -174G/C No genotype 
association with 
hypertrophy
(Patel et al., 2000)
Recent studies have looked at polymorphisms in RAS as a candidate system 
demonstrating a cumulative influence on hypertrophy (Ortlepp et al., 2002; Perkins et 
al., 2005) though, in the latter study this was only evident in the subgroup with no
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previously identified mutation. A further study has now demonstrated this ‘additive’ 
effect prospectively in a group of paediatric HCM patients (Kaufman et al., 2007). 
Association studies are not the only method of searching for ‘modifier genes’ -  a 
genome wide linkage study has identified the 1 Op 13 locus as having a very strong 
‘modifier’ effect in HCM (Daw et al., 2007). ITGA8 and C10orf97 genes located in this 
region are both plausible candidates, being abundantly expressed in the heart and having 
cell-matrix adhesion and apoptosis functions respectively.
In summary, there is currently functional evidence and some epidemiological evidence 
that ACE  I/D polymorphism (and other polymorphisms in RAS) are associated with a 
modifying effect on HCM phenotypes.
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Chapter 2: Materials and Methods
MATERIALS
Reagents
DNA Extraction: All reagents were supplied by Sigma (Poole, UK).
Polymerase Chain Reaction: PCR primers and Taq polymerase were supplied by Gibco- 
BLR Ltd (Paisley UK). Restriction enzyme (Mlu-I) was supplied by New England 
Biolabs Inc (UK). dNTPs were supplied by Pharmacia Biosystems Ltd (Milton Keynes, 
UK).
Gels: 37.5:1 acrylamide:N,N’-methylenebenebisacrylamide was supplied by Protogel, 
National Diagnostics (Hull, UK). TEMED (NNN’^ ’-tertramethylethylethylenediamine 
and ammonium persulphate (APS) were supplied by BDH (Leicestershire, UK).
Commonly used stock solutions 
DNA Extraction:
1M M gCh: 20.33g MgC^ dissolved in 100ml in dH2 0 .
1M Tris pH  7.5: 12.1 lg Tris, made up to 100ml in dH20, Correct pH to 7.5 and 
autoclaved.
Sucrose lysis mix: 109.54g sucrose, 5ml 1M MgCl2,10ml 1M Tris pH7.5, 10ml Triton- 
X-100, made up in 1000ml in dH20 and stored at 4°C.
0.5M Na2EDTA: 37.22g EDTA, made up to 200ml in dH20 . Adjust with NaOH to pH 
8.0
10%SDS: lOg Sodium dodecyl sulphate, made up in 100ml in dH20.
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Nuclear lysis mix: 1ml 1M Tris-HCl pH8.2, 2.34gNaCl, 0.4ml 0.5M Na2EDTA pH 8.0, 
10ml 10%SDS, made up to 90ml in dH20 .
5M  Sodium perchlorate: 70.24g sodium perchlorate, made up to 100ml in dH20 .
TE buffer pH  7.6: 1.21 g Tris, 0.37g EDTA, made up to 1000ml in dH20 .
MADGE gels: For each gel a solution was made up containing:- 
5mls of lOxTBE , 12.2mls 30% acrylamide-bisacrylamide (in a ratio of 19:1), 32.5mls 
o f distilled dH20 , 150pl N ’-tetramethylethylenediamine (TEMED), 150pl 25% 
ammonium per sulphate
TBE (lOx Tris-Boric acid-Ethylenediaminettraacetic acid contained:- 0.9M Tris, 0.9M 
Ortho-boric acid, 0.2M ethylenediaminetetraacetic acid)
TaqMan assays: All TaqMan assays were obtained from Applied Biosystems 
(California, USA). TaqMan Absolute QPCR Rox mix and 384 well plates were supplied 
by ABgene (Surrey, UK).
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METHODS
Study samples
HIFMECH: Hypercoagulability and Impaired Fibrinolytic Function Mechanisms Study 
(HIFMECH)
The HIFMECH study was designed to study genetic and environmental mechanisms 
contributing to the higher cardiovascular risk in Northern compared to southern Europe 
(Juhan-Vague et al., 2002). The study sample of Caucasian male first myocardial 
infarction survivors below 60 years o f age were recruited from four European centres 
(Northern European-Stockholm, London; Southern European-Marseille, San Giovani 
Rotondo) (n=598). Subjects with familial hypercholesterolemia and insulin-dependent 
diabetes mellitus were excluded. A selection of randomly-selected age-matched healthy 
controls was also recruited from each catchment area (n=653). The study was 
performed in accordance with the guidelines in The Declaration of Helsinki and 
approved by local ethics committees. Written informed consent was obtained from all 
subjects. The patients and control subjects were examined in parallel in the early 
morning after an overnight fast, and a blood sample was also obtained. Post-infarction 
patients were investigated 3 to 6 months after the acute event.
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The Second Northwick Park Heart Study Cohort (NPHSII)
The Second Northwick Park Heart Study (NPHSII) was recruited by the Medical 
Research Council Cardiovascular group at The Wolfson centre for Preventative 
Medicine. In brief, 3012 unrelated healthy Caucasian middle-aged male subjects (mean 
age 56.1+3.5 years) recruited from nine UK general practices, detailed elsewhere were 
prospectively followed for up to 15 years (Miller et al., 1995). The study was approved 
by the institutional ethics committees and performed in accordance with the declaration 
of Helsinki. All subjects gave written informed consent.
Baseline characteristics were ascertained by means of a questionnaire at entry into the 
study, with SBP recorded twice with a random zero mercury sphygmomanometer after 
five minutes seated. Exclusion criteria at baseline were a history of MI, cerebrovascular 
disease, life-threatening malignancy or regular cardiovascular medication with aspirin, 
anticoagulants or anti-hypertensives. At entry, a 5ml EDTA blood sample was 
obtained, from which genomic leukocyte DNA was extracted. Time to first CHD event 
(defined as sudden cardiac death, symptomatic/silent MI (the appearance of a new 
major Q wave on the follow up ECG, using Minnesota codes 11, 12.1 to 12.7, 12.8 plus 5i or 
52, or coronary revascularisation) was recorded, yielding only one event/subject (Miller 
1995). Cases of T2D at baseline were identified by self report. Exclusion criteria 
precluded subjects requiring insulin or oral hypoglycaemics from entry into NPHS II. 
New cases were identified by practice note search for physician diagnosed and treated 
T2D according to current national guidelines (Gable et al., 2006). The reporting o f T2D 
was done thoroughly and systematically, and after 15 years 288 CHD events occurred in 
2782 of the subjects with DNA available for analysis. There were 76 cases of T2D at 
baseline and by 15 years a further 169 cases had been identified.
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Retrospective study of Hypertrophic cardiomyopathy (HCM)
The study cohort consists of 541 unrelated patients diagnosed with HCM, assessed at St 
George’s Hospital, London, and Heart Hospital, London UK between 1988 and 2006. 
Mean age was 38.5 years (SD 17.4) with 62% being men. 17 individuals were under age 
o f 16.
The diagnosis of HCM was based on the echocardiographic evidence of left ventricular 
hypertrophy more than 2 SD for age and sex or in accordance with criteria for the 
diagnosis of familial disease in patients with at least one first degree relative who had an 
unequivocal diagnosis (Richardson et al., 1996; McKenna et al., 1997). Patients with 
other cardiac or systemic diseases that can produce hypertrophy were excluded.
Clinical evaluation
Initial evaluation included history, clinical examination, 12 lead ECG, 
echocardiography, and symptom limited cardiopulmonary exercise testing. A blood 
sample was also taken from which genomic leukocyte DNA was extracted.
Survival data and clinical status were collected at subsequent clinic visits for patients 
followed up at these institutions, and by direct communication with patients and their 
general practitioners when followed up elsewhere. This was obtained in 485 patients 
with a mean follow up of 6.65 years (range of 0.56 to 19.1 years with no event and 5.14 
years with a range of 0.27 to 16.25 years in those with an event).
390 (72%) of the 541 patients underwent serial echocardiography to study changes in 
left ventricular size, left atrial size, maximal wall thickness and systolic function over
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time. Change in NYHA functional class and change in peak VO2 during follow up was 
also studied.
Echocardiography
Echocardiography was performed with an Acuson 128 XP/10 (Mountain View, 
California, USA), GE Vingmed system V (GE Ultrasound Europe, Horten, Norway), or 
a Hewlett Packard Sonos 1000 (Hewlett Packard, Andover, Massachusetts, USA). 
Standard views for M mode and two dimensional studies were obtained. Left ventricular 
end diastolic (LVED) and left ventricular end systolic diameters (LVES) were measured 
from two dimensional and M mode images obtained from parasternal long axis views. 
Fractional shortening (FS) was calculated by the formula ((LVED -  LVES)/LVED) x 
100. Left atrial size (LA) was measured on M-mode.
The magnitude and distribution of left ventricular hypertrophy were assessed in the 
parasternal short axis view and confirmed from parasternal long axis and apical views. 
The ventricle was divided into four regions: anterior septum, posterior septum, lateral 
wall, and posterior walls. Wall thickness was measured at the level of the mitral valve 
and papillary muscles in each of the four myocardial segments. Maximum left 
ventricular wall thickness or Max LVWT was defined as the greatest thickness in any of 
these segments. Patients underwent symptom limited cardiopulmonary exercise testing 
in accordance with previously published methods (Sadoul et al., 1997). All 
measurements are quoted in millimeters except FS which is a percentage.
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End points for the survival analysis were as follows:
Sudden cardiac death: witnessed sudden death with or without documented ventricular 
fibrillation, death within one hour of new symptoms, or nocturnal death with no 
antecedent history of worsening symptoms; Heart failure death: death preceded by signs 
and symptoms o f heart failure or cardiogenic shock; Other cardiovascular death: deaths 
caused by stroke, pulmonary or systemic embolism, and myocardial infarction; Non- 
cardiovascular death: deaths caused by known non-cardiovascular and unknown events; 
Heart transplantation; In patients who had resuscitated sudden cardiac arrest during 
follow-up or an implantable cardioverter-defibrillator (ICD) as primary prophylaxis the 
first appropriate shock during follow-up was coded as an outcome in the survival 
analysis.
All cause mortality was defined as sum of all-cause deaths, cardiac transplantations, VF 
arrests and ICD discharges. Cardiac mortality was defined as sum of cardiac deaths (all 
cause minus non-cardiac), cardiac transplantations, VF arrests and ICD discharges. 
Changes in left ventricular parameters and left atrial size, and change in peak VO2 
during follow up were also studied. ACE  genotype was obtained as described later in 
this chapter.
This study was approved by the local research ethics committee and subjects gave their 
informed consent.
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DNA Extraction from Blood -  The “Salting Out Method”
Leukocyte DNA for genotyping had previously been extracted for all studies from 
whole blood using the “salting out” method (Miller et al., 1988). Briefly, the cell lysis is 
achieved with a sugar lysis buffer followed by nuclear lysis using the defined nuclear 
lysis buffer. De-proteinisation is performed with sodium perchlorate. The DNA was 
extracted using chloroform and then precipitated from the aqueous phase using ethanol. 
The extracted DNA was dissolved and stored in TE Buffer. All samples were carefully 
logged and entered into a database with a unique identifier in order to preserve the 
anonymity o f individuals in the study. This stock DNA was used to prepare working 96 
well arrays for genotyping.
Working DNA was standardized to a concentration of 15ng/pl. This was achieved by 
calculating the volume of DNA required to be added to 750 j l a 1 of dLLO to achieve this 
concentration on the basis of the absorbance o f a l Ojul sample of stock DNA. Stock 
arrays were created in labelled 96-well Beckman’s array. These were stored at -20°C.
To create working arrays, lOOpl of each sample was removed from the stock array, and 
transferred to another labelled 96-well array.
Polymerase Chain Reaction
In brief, the technique of PCR relies on the fact that the DNA strand is denatured into 
single strands by heat, and will anneal with primers and nucleotide bases to reform a 
double strand on cooling. The first step is therefore a short high temperature period to 
denature the DNA. This initial stage is followed by cooling in the presence of primers
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that are complementary to the DNA either side of the sequence to be studied. These 
primers anneal, and a DNA polymerase adds nucleotides base by base, thus replicating 
the DNA. The polymerase used is derived from the bacterium Thermus aquaticus ( Taq) 
and is heat stable. It therefore does not need to be replenished after each cycle of 
heating and cooling. This technique allows very small initial amounts of DNA to be 
increased in quantity until there is sufficient DNA for genotyping to be performed.
Sample Preparation for Polymerase Chain Reaction
Following extraction and dispensing into working 96-well arrays, DNA samples were 
prepared for PCR by centrifuging the DNA working-array at 1500g for 1 minute. This 
was to ensure that all the DNA dilutions were at the bottom of their respective wells, 
thus reducing the possibility of cross-well contamination when the array lid was 
removed.
Two and a half microlitres of each sample was then removed from each array and 
transferred into a standard 96-well PCR plate (Omniplate, Hybaid) using a Finnipipette 
multichannel dispenser (Life Sciences, Basingstoke, Hants, UK). Positive and negative 
controls were utilised to ensure accuracy. Extreme care was taken to ensure that 
samples were place in the identical orientation as in the original arrays. Loaded 
Omniplates were then centrifuged at 1500g for 30 seconds to ensure that the DNA was 
at the bottom of each well, and then dried on a Thermal Cycler block (MJ Tetrad DNA 
Engine Thermocycler) at 90°C for 10 minutes.
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A bulk-mix of reagents was made up for each PCR, allowing adequate volume for the 
planned number reactions, with an additional 10% added to ensure that the mix would 
not run short. PCR primers and Taq polymerase (Gibco-BLR LTd., Paisley UK) were 
kept on ice and added last.
Polymerase chain reaction were performed in a total volume of 20pl. Each reaction 
contained lx concentration of polmix (50mM KC1, lOmM Tris-HCl (pH 8.3), 0.2mM 
dATP, dGTP, dTTP and dCTP) or 1 x NH3 buffer (16mM (NH4)2S04, 67mM Tris-HCl 
(pH 8.4), 0.01% Tween 20, 0.2mM of each dNTP) and MgCl2, lOpmol of each primer 
and 0.3U of Taq polymerase. Magnesium concentration varied with each PCR.
The PCR mix was added to each well o f the PCR plate using an automatic Biohit 
repeating dispenser (Alpha Laboratories, UK). Each sample was overlaid with 20pl of 
mineral oil to prevent evaporation. The microtitre plate was then sealed with clear 
sticky plastic lid and carefully labelled. Plates were centrifuged at lOOOrpm for 30 
seconds to ensure good mixing of the reaction components in each well. PCR 
amplification was performed on an MJ Tetrad DNA Engine Thermocycler, using cycle 
conditions specific to each PCR. A description o f the individual primers and conditions 
for the ACE  1/D variant can be found at the end o f this section.
Detection o f DNA (Agarose gels)
In order to check the successful amplification and size of PCR products, agarose gels 
were utilised. For a 2% gel, 2 grams o f agarose was mixed with 100ml of 1 xTBE 
solution containing lOpL o f Ethidium bromide (lOpg/pL). A microwave oven was used
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to heat the mixture and dissolve the agarose. The melted agarose was poured into a 
plastic gel tray (10 x 14cm) and a comb inserted. Solid gels were placed into an 
electrophoresis tank containing 750ml of lxTBE buffer solution. 2pl of MADGE 
loading dye was added to 5pL PCR product and the entire volume was mixed 
thoroughly and placed in the separate, submerged wells of the gel. 2pl of a 1Kb ladder 
(Invitrogen, Paisley UK) was pipetted into the central well in order to size relevant 
products. All agarose gels were run at 100 volts (v) for a minimum of 30 minutes.
Restriction digestion
Restriction enzymes are derived from bacteria, and cleave double stranded DNA at a 
particular sequence. The enzyme translocates along the DNA until a particular 
recognition site is reached, where the DNA is cut. The restriction enzyme is sensitive 
even to a single base change in the recognition sequence, and thus can be used to detect 
point mutations and single base polymorphisms. A single base change can either 
eliminate or create a cutting site for a particular enzyme.
A restriction enzyme digest mix with the recommended buffer system was made up in a 
lml Eppendorf tube on each occasion, containing sufficient enzyme to digest the PCR 
products in each well of the PCR plate. 5pl of digestion mix was then added to 8 j l x 1 of 
each reaction product using a repeater pipette as for the PCR mix. Each omniplate was 
then centrifuged at 200g for thirty seconds to ensure that the PCR product and 
restriction enzyme were mixed well. The PCR/digestion mix was then incubated 
overnight at the recommended temperature.
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In view of the ACE  I/D polymorphism being studied was a deletion polymorphism, 
specific variants were found after the PCR which could be accurately resolved by 
Microtitre Array Diagonal Gel Electrophoresis (described below) therefore there was no 
need in this case to carry out restriction digestion.
Microtitre Array Diagonal Gel Electrophoresis (MADGE)
The DNA fragments produced by restriction enzyme digest were separated by 
electrophoresis on a non-denaturing polyacrylamide gel, using Microtitre Array 
Diagonal Gel Electrophoresis (MADGE) (Day et al., 1995). This technique makes it 
possible to electrophorese all the 96 wells o f a standard PCR plate on a single gel, by 
allowing the samples to run diagonally. Use o f MADGE allowed the 96 well DNA array 
format to be retained throughout the screening process.
MADGE consists of an open arrangement of 8x12 wells each 2mm deep. The wells are 
arranged at an angle o f 71.2 degrees to the short axis of the array, but perpendicular to 
the long-axis o f the Perspex formers used (Figure 2.1). Before making the mix, glass 
plates o f appropriate size (160 x 100 x 2mm) were rigorously cleaned and hand dried. 5 
drops of y-methacryloxypropyltrimethoxysilane ( ‘sticky’ saline) were spread across the 
plates and left to air-dry. Polymerisation o f the MADGE mix was initiated by the 
addition o f ammonium persulphate and the solution was mixed and quickly poured into 
the three-dimensional former. A glass plate was then gently placed over the mould 
(saline side facing downwards) taking care not to trap any air bubbles. This was then 
left for fifteen minutes to set, using a small weight to ensure that the glass did not slip 
whilst the gel was setting. Excess gel was trimmed from the edges o f the MADGE
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former before the glass plate and attached gel were then prized away from the plastic 
former.
Gel Staining and Loading
Prior to loading a gel with digested PCR product, each gel was stained with Ethidium 
Bromide (EtBr). This was achieved by placing them individually in a Stuart box, 
shielded from direct light, containing 100ml of lx  TBE and lOpl EtBr for 20 minutes.
Whilst the gels were being stained the PCR-digest product was prepared for loading 
onto the MADGE gel. 2pl o f formamide dye (98% formamide, 10mmol/l EDTA,
0.025% xylene cyanol, 0.025% bromophenol blue) was added to each well of a new 
round-bottomed loading tray, followed by 5 pi of each digested sample, using a multi­
channel pipette to pick up the samples from under the oil in the omniplates. The 
digested samples were gently mixed, by aspirating the formamide dye-digest mixture 
up and down several times into the pipette, before dispensing them on the digest plate. 
After placing the stained MADGE gel into an electrophoresis tank containing 1000ml of 
lxTBE, a multi-channel pipette was then used to transfer 5 pi of this digest/dye mixture 
to the wells o f the gel. At all times the samples were kept in the same layout as on the 
PCR tray, allowing each sample to be easily identified without being re-labelled. The 
gel was electrophoresed at 150 volts for 40 minutes.
Following electrophoresis the gel was viewed and photographed under ultraviolet light 
using the UVP Gel Documentation System. Care was once more taken to ensure the 
correct orientation o f the MADGE under UV. This was ensured by always placing the
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well corresponding to grid-reference “A l” in the bottom left-hand comer of the UV- 
viewing box. The image thus produced was used for genotyping. An example of typical 
MADGE gel is shown in Figure 2.1. All genotyping was performed in a double blind 
fashion using both positive and negative controls. The results were rechecked by two 
individuals at the time of MADGE imaging and during data entry into the computer 
database. Any apparent genotype differences were resolved by repeat PCR. Overall 
there was excellent reproducibility with >95% consistency between observers.
Figure 2.1 ACE  I/D Genotype Resolved on MADGE
ACE II 
ACE I/D 
ACE DD
Direction o f Electrophoresis 
TaqMan® genotyping 
TaqMan® assay technology
The principle behind the TaqMan® reaction is described in Figure 2.2. The method 
involves the inclusion of two fluorescent, dye-labelled probes for each allele of a
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specific variant. The allele specific probes each contain a short sequence of DNA, a 
reporter dye (labelled VIC™ or FAM™ depending upon the allele) at the 5’ end, and a 
non-fluorescent quencher (NFQ) dye at the 3’ end. During the PCR process, 
forward/reverse oligonucleotides as well as the labelled probes, anneal to the DNA of 
interest (Figure 2.2A). Amplitaq Gold® DNA polymerase is able to replicate the single 
strand o f DNA until it reaches the labelled probe. Any non-specific binding results in a 
weakened interaction o f the labelled probe with the DNA and displacement of the intact 
probe (no cleavage of the dye from the quencher) (Figure 2.2B). If the probe is entirely 
complementary (hence allele specific probes) to the annealed DNA sequence, the 5’ to 
3 ’ exonuclease activity o f the enzyme results in the cleavage of the 5’ dye from the rest 
o f the probe (Figure 2.2C). The close proximity of the dye to the quencher usually 
prevents any significant fluorescent emission. However, once the dye is cleaved, 
fluorescence increases with each round o f DNA replication (Figure 2.2D). A 7900HT 
Sequence Detection machine (Applied Biosystems, California USA) is then able to 
determine the relative levels of either the VIC or FAM dyes, thereby determining the 
specific genotype.
Figure 2.2 Schematic of the TaqMan® assay system. A. Represents the annealing o f the 
fluorescent probes and oligonucleotides. B. If the fluorescent probe is not identical to 
the DNA sequence, the probe is displaced by the Taq. C. Successful annealing leads to 
5’-3’ exonuclease o f the probe.
D. The VIC™ and FAM™ labels fluoresce and are picked up by the Taqman® 
machine.
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Preparing the DNA
In contrast to traditional PCR and MADGE based technology, the TaqMan® system 
enables high throughput genotyping in a 384 well format. In order to use this system, 
DNA was first standardised to an optimal concentration of 1.25ng/pL using the same 
methodology described earlier. A Biomek 2000 robot (Beckman-Coulter, High 
Wycombe UK) was used to aliquot 4pL o f standardised DNA from a 96 well stock 
array into a 384 well plate (5ng total) with 16 wells left blank to act as negative 
controls. A data sheet was also compiled in order to identify each well to patient ID
number (Figure 2.3). The plates were dried out overnight at room temperature in sterile 
paper bags and stored until use.
Figure 2.3 Schematic of a 384 well plate. Each colour represents an individual 96 well 
plate as pipetted by the Beckman robot.
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TaqMan master mix
Forward/reverse oligonucleotides and labelled probes were ordered using the ‘Assay by 
demand’ service available on the Applied Biosystems website 
(www.appliedbiosystems.com). Table 2.1 lists the assay successfully designed by 
Applied Biosystems for genotyping of the SNP (rs4341) which is in complete LD with 
the ACE I/D polymorphism. For each 384 well plate, a master mix was made of the 
ABgene QPCR Rox mix, the individual assay mix, and distilled sigma water. 4pL of 
mix was then applied to each well of the 384 plate using a manual Eppendorf 300, 8 
channel multi-dispensing pipette and centrifuged (Sigma 4-15) at 200g for thirty 
seconds. A clear plastic lid (ABgene, Surrey UK) was applied to seal the plate.
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Reading and entering o f genotypes
A standard two step heat cycle program on a Thermohybaid (Basingstoke, UK) 384 
well heated block was used to initiate the PCR reaction (95°C for ten minutes, followed 
by 40 cycles of 95°C for 15s and 60°C for lmin), and all plates were then read on a 
7900HT Sequence Detection machine (Applied Biosystems). The 7900HT Taqman® 
machine uses SDS software 2.1 (Applied Biosystems) in order to differentiate the 
different genotypes (Figure 2.4). SDS 2.1 produces an allelic discrimination plot as well 
as assigning genotypes automatically to an excel file containing patient ID numbers 
according to array position. To ensure no incorrect inputting of data, a second 
researcher validated all the genotypes before the data was finally entered into the 
analysis database.
Figure 2.4 Screen shot o f a typical allelic discrimination plot. The three different 
coloured dots represent each individual genotype: Blue and red represent homozygotes 
with the green dots representing heterozygotes. Light blue crosses show the negative 
controls. Those dots which were not tightly clustered (circled in the figure) to a 
particular group were re-genotyped.
59
Marker:
Allelic D iscrim  nation Plot
Cat |Undeter... “3 I
1.3
Allele X (TB8-A)
Legend
X  Undetermined
*  AHeteX
*  O r t h
*  Allele ¥
■ NTC
Specific Gene variants
ACE I/D polymorphism (rs l799752) 
rs4341 (O G ) - 100% LD with I/D variant
The I/D polymorphism was genotyped in HIFMECH using PCR and MADGE method. 
In NPHS2 genotypes were determined with the help of Jutta Palmen by PCR and 
MADGE for approximately 87% of sample and using Taqman genotyping for rs4341 
for the remaining samples. One DNA array (94 samples) was genotyped for both ACE 
I/D and rs4341 polymorphisms with 100% concordance. Rs 4341 was genotyped 
exclusively in the HCM cohort with the help of Kah Wah Li. The details of the 
Oligonucleotides and PCR conditions can be found in table 2.1. The Taqman 
oligonucleotides and probes can be found in table 2.2.
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Table 2.1 PCR conditions for genotyping by RFLP
Variant
Oligonulceotides (2 FORWARD 
and 1 REVERSE)
DNA (pi) 
POLMIX 
BSA
MG(mmol)
Conditions
(OC)
Fragment
Length
(bp)
FH76 5 ’- CAT CCT TTC TCC 5 MINS @ 95
CAT TTC TC -3’ 1.5 45s @ 95 85
ACE  I/D
FH77 5 ’- TGG GAT TAC AGG NH4 45s @ 54 (Deletion)
CGT GAT AC AG -3’ YES 30s @ 72 65
FH78 3 ’- ATT TCA GAG CTG 
GAA TAA AAT T -5’
1.5 (32 CYCLES) 
5 MINS @ 72
(Insertion)
Table 2.2 Taqman assays design for rs4341
Variant Primers Probes
Rs4341 FOR: VIC TCAAGCCATTCAAAC NFQ
CCTTACAAGCAGAGGTGAGCTAA FAM CAAGGCATTCAAAC NFQ
REV:
CCATCACATTCGTCAGATCTGGTA
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Statistical analysis
Statistical analysis was performed using SPSS (version 12.1, SPSS Inc., Chicago) or 
‘Intercooled STATA’ package (version 8.2, STATA Corporation, Texas). The analysis 
was performed by Jackie Cooper, Fotios Drenios and myself. For gene association 
analysis, data are reported for those individuals amongst whom high-throughput 
genotyping was successful.
Deviations from Hardy-Weinberg equilibrium were considered using chi-squared tests. 
Hardy-Weinberg equilibrium gives the expected genotype distribution based on the 
observed frequency of the rare allele (<q) and common allele (p) as p 2+2pq+q2, where p 2 
is the predicted frequency for homozygosity o f the common allele, q is the predicted 
frequency for homozygosity o f the rare allele and 2pq, the heterozygotes. These 
frequencies are expected provided the sample is drawn from a population with random 
mating and no strong selection.
Specific details are included in the relevant chapter but in general, allele frequencies, 
odds ratios and hazard ratios are shown with the 95% confidence interval. Analysis of 
variance (ANOVA) was used to assess the association between genotypes and baseline 
characteristics on normally distributed data, or after appropriate transformation. Chi- 
squared tests were used to compare differences in categorical variables by genotype.
No adjustment was made for multiplicity o f testing. Whilst making such an adjustment 
reduces the type I error, it leads to increases in the type II error, and fewer errors of 
interpretation occur when no adjustment is made. However, analysis always followed an 
a-priori hypothesis or design. In all cases a P value of less than 0.05 was considered 
statistically significant.
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In NPHSII survival analysis with respect to the prospective risk of CHD or type 2 
diabetes was carried out using Cox proportional hazards model, ‘failure’ being the first 
CHD event or diagnosis o f type 2 diabetes. Results are presented as hazard ratios (HR) 
with their corresponding 95% confidence interval (Cl). To allow for differences in 
baseline data according to age and practice, age was included as a covariate in the 
model and data stratified by practice.
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Chapter 3: Impact of ACE  (I/D) polymorphism on Coronary Heart Disease: 
Interaction with Lipids and Regional Effect 
Introduction
The genetic contribution to CHD is likely to be based on many genetic variants 
interacting with each other and with environmental influences, with each variant 
exerting a small effect (Suh and Vijg, 2005). The RAS is a likely candidate system in 
CHD pathogenesis, with Angll in particular having several strong pro-atherosclerotic 
properties (Wang et al., 2001; Anderson et al., 2000; Daemen et al., 1991), and RAS 
inhibition being protective in CHD (Yusuf et al., 2000; Fox et al., 2003). Gene 
polymorphisms affecting levels (and function) of RAS components (e.g. I/D 
polymorphism in ACE  explaining half o f the variance of plasma ACE concentration 
(Rigat.B. et al., 1990)) are therefore ideal tools to study CHD risk.
The impact of the ACE  I/D polymorphism on risk of CHD has been widely studied since 
Cambien (Cambien et al., 1992) described a strong association of the D allele with risk 
of MI. Large cohort studies have been unable to replicate this association (Keavney B. et 
al., 2000) with a meta-analysis suggesting that the risk of MI associated with carrying 
the DD genotype was only 1.22 [95% Cl 1.11 -1.35] (Morgan et al., 2003). More 
recently, the ACE  I/D polymorphism has been shown to modify the risk of complex 
phenotypes such as CHD, CVD and hypertension in a large prospective study - the 
Rotterdam study, through interaction with environmental stimuli such as smoking 
(Sayed-Tabatabaei F.A. et al., 2005; Schut et al., 2004a; Sayed-Tabatabaei F.A. et al.,
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2004), age (Sayed-Tabatabaei F.A. et al., 2005; Schut et al., 2004a; Mattace-Raso F.U.S. 
et al., 2004) and blood pressure (Schut et al., 2004b).
Interaction between smoking and the ACE polymorphism, has been reported to lead to (i) 
a higher CVD mortality at a younger age (Sayed-Tabatabaei F.A. et al., 2005), (ii) 
higher systolic blood pressure (SBP) and a higher risk of hypertension also in a younger 
age group (Schut et al., 2004a) and (iii) a significantly greater carotid IMT (Sayed- 
Tabatabaei F.A. et al., 2004). A relationship between age and this polymorphism has 
also been reported in association with carotid stiffness (Mattace-Raso F.U.S. et al., 2004) 
along with an interaction between the ACE  D allele and hypertension leading to a higher 
risk o f heart failure (Schut et al., 2004b). Thus a likely reason for the many negative 
association studies in the case o f this polymorphism was the failure to evaluate GEI.
Regional differences in CVD mortality exist in Europe, with a higher mortality rate in 
Northern Europe compared to Southern Europe (Sans et al., 1997; Keys, 1975). CHD 
differences between populations are only partly explained by differences in classical 
CHD risk factors, so variation in genetic predisposition and subsequent GEI are likely to 
be important as well (Kuulasmaa et al., 2000). The aim of this study was therefore to 
investigate whether the effect o f the ACE  I/D polymorphism on MI risk would differ by 
geographical location within Europe. The hypothesis was tested that this polymorphism 
would be interacting with a specific regional environment to determine the regional MI 
risk.
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Methods
The HIFMECH study (Juhan-Vague et al., 2002) was designed to examine genetic and 
environmental mechanisms contributing to the higher cardiovascular risk in Northern 
compared to Southern Europe. Caucasian male first MI survivors were recruited from 
Northern Europe (Stockholm, London) and Southern Europe (Marseille, San Giovanni 
Rotondo) (n=532) with age matched healthy controls (n=574) from the same locations. 
For full details see Chapter 2.
ACE  genotype using the PCR MADGE method (as described in Chapter 2) (O'Dell S.D. 
et al., 1995) was obtained in 523 cases and 560 controls.
Statistical analysis
Statistical analysis was performed using SPSS (version 12.1, SPSS Inc., Chicago) and 
‘Intercooled STATA’ package (version 8.2, STATA Corporation, Texas). The analysis 
was performed by Jackie Cooper and myself. The a priori hypothesis was followed, and 
analysis was carried out in the North and South separately by cases and controls. 
Differences in baseline variables between North and South (by cases and controls) were 
analysed by ANOVA if normally distributed (or after appropriate transformation), and 
by Chi-squared tests if categorical. These differences were adjusted for age in view of 
the likely confounding effect it could play on each variable. Conditional logistic 
regression models were used for comparison o f variables from cases and controls by 
region. Deviations of allele frequencies from Hardy-Weinberg equilibrium were 
considered using chi-squared tests. Allele frequencies are shown with the 95% 
confidence interval.
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Analysis o f variance was used to assess the association between genotypes and baseline 
characteristics on normally distributed data, or after appropriate transformation. Chi- 
squared tests were used to compare differences in categorical variables by genotype. 
Odds Ratio for MI in genotype groups were calculated using conditional logistic 
regression models and subsequently adjusted for important CHD risk factors - age, 
smoking, cholesterol, triglyceride and BMI. Controls were matched to cases within 
centres so analysis took account of the centre. Interactions were assessed by standard 
methods as deviations from multiplicative effects.
Results
For all samples the distribution of genotypes were as expected for Hardy-Weinberg 
equilibrium. There were no significant differences between any trait in the whole and 
genotyped sample (Table 3.1).
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Table 3.1 Differences in variables between total sample and genotyped sample
Healthy Controls Cases
Variable North South North South
Age
(years)
Total
sample
52.7 (5.0) 
n=253
50.5 (5.6) 
n=321
53.1 (5.1) 
n=233
51.0 (5.5) 
n=299
Genotyped
sample
52.7 (5.0) 
n=245
50.4 (5.6) 
n=315
53.1 (5.1) 
n=232
51.0 (5.5) 
n=291
BMI*
(kg/m2)
Total
sample
25.8(3.1)
n=253
26.4 (3.2) 
n=322
27.2 (3.4) 
n=229
26.9 (3.3) 
n=299
Genotyped
sample
25.8(3.1)
n=245
26.4 (3.2) 
n=316
27.2 (3.3) 
n=228
26.9 (3.3) 
n=291
SBP* / 
mmHg
Total
sample
130.2(15.8)
n=251
126.2(13.1)
n=322
129.5(17.7)
n=228
126.4(16.2)
n=294
Genotyped
sample
130.1 (15.8) 
n=243
126.2(13.1) 
n=316
129.5(17.8)
n=227
126.5(16.3)
n=286
Choi Total
sample
5.71 (0.99) 
n=233
5.39 (0.94) 
n=321
5.66(1.22)
n=215
5.18(1.11)
n=286
Genotyped
sample
5.71 (0.99) 
n=225
5.39 (0.94) 
n=315
5.67(1.21)
n=214
5.17(1.12)
n=278
TG 1 Total
sample
1.52 (0.60) 
n=233
1.39(0.61)
n=321
1.99 (0.83) 
n=215
1.79 (0.72) 
n=286
Genotyped
sample
1.51 (0.59) 
n=225
1.39 (0.61) 
n=315
1.99 (0.83) 
n=213
1.78 (0.71) 
n=278
ApoB+ Total
sample
98.2 (23.5) 
n=233
94.1 (20.2) 
n=321
107.7(28.1)
n=215
96.5 (22.4) 
n=286
Genotyped
sample
98.0(23.1)
n=225
94.2 (20.3) 
n=315
107.8 (28.1) 
n=214
96.2 (22.5) 
n=278
TG Triglyceride 
* geometric mean (approx sd)
'means and sds calculated from log-transformed data 
+means and sds calculated from square root transformed data
P values for all comparisons between total and genotyped sample were non-significant
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The baseline characteristics by cases and controls, and genotype distributions in the 
North and South are shown in Table 3.2. With regard to controls, in the North they had 
a significantly lower BMI and a higher SBP, cholesterol, triglycerides and apoB than 
those in the South, with no significant difference in smoking. For cases, in the North 
they had a significantly higher SBP (borderline), cholesterol, triglycerides and apoB 
than those in the South. There was a trend for a higher BMI in the North and smoking 
rate was substantially higher in the South than the North. In terms o f case-control 
differences, in the North the cases had significantly higher BMI, triglycerides, apoB and 
much higher smoking rates than controls. The reason for the lower (non-significant)
SBP and cholesterol in cases may be related to the medications given to MI survivors.
In the South, cases had a higher BMI, SBP (trend), triglycerides, apoB (trend), and 
smoking levels than controls. Again, the lower cholesterol in the cases may be related to 
medication.
Table 3.2 (overleaf) Baseline characteristics o f genotyped sample including ACE  gene 
frequencies
Values are mean (SD); n, number o f  subjects in group; BMI, body mass index; BP, 
blood pressure; (1) Geometric mean, and SD calculated from log-transformed data. (2) 
Mean and SD calculated from square root transformed data. (3) values adjusted for age. 
(4) p-values for continuous variables are from analysis o f variance, unless otherwise 
stated, p-values for categorical variables are from chi-squared tests. (5) p-values are 
from conditional logistic regression models.
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Controls
North South North-South difference(3),(4)
Cases
North South North-South difTcrence(3),(4)
Cases vs Controls 
in N (5)
Cases vs Controls 
in S (5)
Age (years) 5 2 .7 (5 .0 )
n=245
5 0 .4 (5 .6 )  
n = 3 15
< 0.0001 53.1 (5.1) 
n=232
5 1 .0 (5 .5 )
n=291
< 0.0001 0.37 0.23
BMI (1) (kg/m2) 25.8 (3.1) 
n=245
2 6 .4 (3 .2 )  
n = 3 16
0.03 2 7 .2 (3 .3 )
n=228
2 6 .9 (3 .3 )
n=291
0.47 < 0.0001 0.02
Systolic (1) 
BP (mmHg)
130.1 (15.8) 
n=243
126 .2(13 .1)  
n = 3 16
0.001 129 .5(17 .8)
n=227
126.5 (16.3) 
n=286
0.05 0.67 0.79
Cholesterol
(mmol/L)
5.71 (0.99) 
n=225
5.39 (0.94) 
n = 3 15
<0.0001 5 .6 7 (1 .2 1 )
n=214
5 .1 7 (1 .1 2 )
n=278
< 0.0001 0.66 0.01
Triglyceride 
(1) (mmol/L)
.51 (0.59) 
n=225
1.39 (0.61; 
n = 3 15
0.02 1.99 (0.83) 
n=213
1.78 (0.71) 
278
0.003 < 0.0001 < 0.0001
Apo B (2) 
(mmol/L)
98.0 (23.1) 
225
94.2 (20.3) 
315
0.04 107.8 (28.1) 
214
96.2 (22.5) 
278
< 0.0001 < 0.0001 0.25
Smoking
Current+Ex
Never
Genotype
distribution
II/ID/DD
D Allele  
frequency 
(95% Cl)
157(62.1% ) 
96 (37.9% )
201 (62.4%) 
121 (37.6% )
58/110/77 46/156/114
0.54 (0.49- 
0.58)
0.61 (0.57- 
0.65)
0.93 179 (76.8%) 
54(23.2% )
259(86% ) 
41 ( 14%)
0.004
50/117/65 44/156/92
0.53 (0.49- 
0.58)
0.58 (0.54- 
0.62)
< 0.001 < 0.001
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ACE  genotype
The frequency o f the D allele was higher in the South than North in both cases and 
controls, and there was no significant difference in genotype distribution between cases 
and controls in either the North or the South (Table 3.2). When the odds (adjusted for 
age, smoking, cholesterol, triglycerides and BMI) of being a case by ACE  genotype was 
calculated, the presence o f a D allele conferred a 36 % (p=0.29) higher risk o f being a 
case compared to the II genotype in the North, whereas in the South there was only a 
7% higher risk (p=0.81) (Table 3.3). The genotype by North-South interaction was not 
significant (p=0.48) and in the combined data for North and South there was a 20% 
(p=0.2) higher risk o f being a case when having a D allele. The number required to 
detect this interaction with 80% power at the 5% level is 1465 cases and the same 
number o f controls.
In order to explain the higher MI risk in the North, interaction between ACE  genotype 
and those factors that were significantly higher in controls (and cases) in the North 
(Table 3.2) - triglyceride, apoB, cholesterol and SBP were examined. With a 
triglyceride above 1.57mmol/L (median value), the odds of having a MI in the North 
with a D allele was 2.95 (95% Cl 1.50-5.79) vs 2.05 (95% Cl 1.08-3.90) in the South. 
With apoB above 98.5 mg/dL (median value) the odds of having a MI in the North with 
a D allele was 2.33 (95% Cl 1.13-4.83) vs 1.25 (95% Cl 0.65-2.40) in the South. For 
both the triglyceride and apoB however, the interaction term was not significant, and 
these interactions are depicted in Figure 3.1 A and B. The cholesterol interaction was far 
less clear cut: the D allele with a cholesterol above 5.4mmol/L (median value) conferred 
a 71% higher MI risk in the North vs 53% in the South (both results non-significant) but 
MI risk was highest in the South with a cholesterol less than 5.4 with II genotype -  2.87
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(95% Cl 1.14 -  7.19). Genotype interaction with SBP showed no consistent association 
and was not significant (not shown). Interaction with smoking was not carried out in 
view of rates being higher in the South than North.
Table 3.3 Odds Ratios o f MI in North and South Europe with particular reference to 
lipid measures
O dds o f  MI in N orth (95%  C l) Odds o f  MI in South (95%  Cl)
Unadjusted II 1.00 p=0.40 1.00 p=0.88
OR ID/DD 1.22 (0 .77-1 .92) 0.97 (0.62-1.51)
Adjusted II 1.00 p=0.29 1.00 p=0.81
OR* ID/DD 1.36 (0 .77 -2 .42 ) 1.07 (0.63-1.81)
Triglyceride II 1.00 p=0.75 1.00 p=0.88
<1.57 ID/DD 1.09 (0 .52-2 .27) (1) 0.88 (0.47-1.65) (1)
II 2.31 (0 .99-5 .35) 2 .16(0 .87-5 .37)
>1.57 ID/DD 2.95 (1 .50-5 .79) 2 .05(1 .08-3 .90)
ApoB II 1.00 p=0.45 1.00 p=0.81
<98.5 ID/DD 1.02 (0 .47-2 .22) (1) 1.04 (0.55-1.95) (1)
II 1.54 (0 .63-3 .75) 1.35 (0.57-3.20)
>98.5 ID/DD 2.33 (1 .13-4 .83) 1.25 (0.65-2.40)
Cholesterol II 1.47 (0 .60-3 .60) p=0.36 2.87(1 .14-7 .19) p=0.09
<5.4 ID/DD 1 .54 (0 .7 7 -3 .0 5 ) (1) 1.89 (0.93-3.84) (1)
II 1.00 1.00
>5.4 ID/DD 1.71 (0 .89-3 .29) 1.53 (0.73-3.17)
OR -  odds ratio calculated  using conditional logistic regression model. * adjusted for age, smoking, 
cholesterol, triglyceride, BM I. (1) p value for interaction  w ith variable. Controls are m atched to cases 
w ithin centres so analysis takes account o f  centre
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Figure 3.1 A Odds Ratio o f MI by ACE  genotype in those below and above sample 
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Figure 3 .IB Odds Ratio o f MI by ACE  genotype in those below and above sample 
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Discussion
No statistically significant association between genotype and MI risk was demonstrated 
however this was not unexpected. A modestly higher odds ratio for MI associated with 
the D allele was seen in the North , 1.36 (0.77-2.42), which was consistent with the 
meta-analysis risk estimate o f 1.22 (1.11 -1.35) (Morgan et al., 2003). This result 
supports the view that AC E  genotype, in conjunction with other factors, is an important 
but modest contribution to the development of pathological cardiovascular phenotypes. 
In the HIFMECH study, the controls and cases in the North had higher levels of 
cholesterol, triglyceride, apoB and a higher SBP than their counterparts in the South.
The results here suggest that there is an interaction between one or more of these factors 
and the D allele in determining risk o f MI. Despite the most recent literature of 
interaction with ACE  and SBP and smoking, these are unlikely to be playing a role in 
this sample. Though the SBP was significantly higher in the North than South in 
controls and cases the actual difference was small (of the order o f only 3 - 4mmHg) and 
the SBP would certainly have been reduced by drugs in cases. Smoking prevalence was 
higher in the South than North in controls and cases.
The interaction identified here is between theA C E  D allele, elevated triglycerides or 
ApoB and North Europe, in that D allele carriers with elevated lipid measures in the 
North have a substantially (though non-significantly) higher MI risk than D allele 
carriers with elevated lipid measure in the South. The interaction is more convincing for 
ApoB where there is also a marked difference in MI risk not only between D allele 
carriers in North and South, but also between Northern D allele carriers and II 
homozygotes who have elevated ApoB levels - 2.33 (1.13-4.83) vs. 1.54 (0.63-3.75).
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Cambien et al (Cambien et al., 1992) initially reported an ACE DD genotype interaction 
with plasma ApoB levels, finding a risk ratio of 3.2 (95% Cl 1.7-5.9) with low ApoB (< 
1.25g/L) and low BMI (< 26kg/m2) but this has not been confirmed by others (Keavney 
B. et al., 2000). The data here supports the opposite, with the D allele risk being 
statistically significant only in those with high ApoB or triglycerides.
There are possible mechanisms through which this gene-lipid-region interaction may be 
occurring. The higher Angll (and lower Bradykinin) levels (in plasma and tissues e.g. 
arterial wall and myocardium) would lead to a pro-atherosclerotic state in D allele 
carriers through multiple mechanisms, including endothelial ROS production with 
subsequent endothelial dysfunction (Wang et al., 2001; Anderson et al., 2000) and SMC 
hyperplasia (Daemen et al., 1991). Elevated lipid components including apoB and 
triglycerides are robust CHD risk factors (Hokanson and Austin, 1996)(St Pierre et al., 
2006) with evidence for causality - excess intracellular triglycerides promoting 
increased oxidative stress and inflammation (Bakker et al., 2000) and apoB being 
intimately involved in lipid metabolism (Chapman et al., 1988). The combination of 
elevated apoB or triglycerides and raised Angll would therefore predispose certain 
individuals to higher CHD risk. There is also evidence for additional effects between 
lipid and Angll. Hypercholesterolaemia has been shown to increase plasma Angll 
concentrations (Daugherty et al., 2004) and Angll is also involved in LDL oxidation 
and uptake (Keidar et al., 2001). It has therefore been suggested that there is a positive 
feedback relationship with high cholesterol levels increasing Angll and Angll 
increasing lipid uptake (Keidar et al., 2001). Angll has also been shown to increase 
triglycerides (Ran et al, 2004). It is therefore plausible that there may be a positive 
interaction between elevated lipid status and ACE  I/D polymorphism on CHD risk.
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Why this risk is present in Northern Europeans and not Southern Europeans is probably 
due to the presence o f other gene variants or environmental stimuli (e.g. Mediterranean 
diet) that differ between the two regions, affording protection in South Europe or harm 
in North Europe.
This study was underpowered to detect an effect by the ACE{\J\y) genotype on MI risk 
by region. The earlier power calculation demonstrated almost three times more cases 
and controls are needed to confirm or refute if the previous size of effect is correct. This 
again is no surprise when the modest effect o f the polymorphism is considered. The 
case-control design also introduces survivor bias, in that the reason for a genotype being 
overexpressed in the cases could be due to it conferring a survival advantage. Subjects 
from the Northern centres (Stockholm and London) and Southern centres (Marseille and 
San Giovanni Rotondo) were also not uniform when examined with differing levels of 
blood pressure and triglycerides. The suggested evidence for ACE  lipid interaction was 
confounded by a large proportion o f cases being on lipid-lowering treatment. However 
regional differences in all three lipid measures in cases were highly significant and of 
similar magnitude when those cases not on therapy were analysed (Table 3.4).
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Table 3.4 Differences in plasma lipid concentrations amongst cases not on lipid- 
lowering drugs according to region in Europe
Cases NOT on lipid-lowering drugs
Variable North South N vs S3’4
Cholesterol
(mmol/L)
5.93 (1.08) 
n=158
5.30(1.08)
n=198
<0.001
Triglycerides
i
(mmol/L)
2.05 (0.85) 
n=158
1.81 (0.75) 
n=198
0.005
Apo B
(mg/dL)2
115.1 (23.7) 
n=158
97.7(21.8)
n=198
<0.001
Values are mean (SD) with levels adjusted for age1 9Means given are the antilog o f the mean of log transformed data; Means given are 
the square of the mean o f square root transformed data;3 Values are adjusted for age; 4 
P-values are from analysis o f variance
In conclusion, ACE  genotype may interact with higher triglycerides or apoB in males in 
the North Europe to influence MI risk. This may account for a part of the difference in 
CHD mortality between North and South Europe. Further large-scale studies involving 
this polymorphism in cardiovascular disease, avoiding direct associations but rather 
targeting interactions with lipids / lipoproteins and other factors, are warranted.
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Chapter 4: Impact of A C E {\M ) polymorphism on Coronary Heart Disease: 
Interaction with Systolic Blood Pressure 
Introduction
As already detailed in the thesis, there is considerable evidence for the involvement of 
the RAS in the development o f atherosclerosis and LVH (Talmud et al., 2007)(Mehta 
and Griendling, 2007). CHD risk and mortality from heart failure are decreased by ACE 
inhibitors (Yusuf et al., 2000; SOLVD Investigators, 1991). In view o f the significant 
association between the ACE  I/D polymorphism and tissue and plasma ACE levels 
(Rigat.B. et al., 1990; Danser et al., 1995), one might anticipate the ACE  D-allele to be 
associated with excess CHD risk. Cambien et al were the first to report such an 
observation (Cambien et al., 1992) however, as in the majority o f single polymorphism 
associations studies further results have been inconsistent, and meta-analysis of 
published data suggest the impact o f ACE  genotype on MI risk to be modest (relative 
risk associated with DD genotype o f approximately 1.2 (Agerholm-Larsen et al., 2000; 
Morgan et al., 2003)).
Such inconsistency and weakness o f effect may, however, reflect the interaction of ACE  
genotype with environmental factors in determining risk. Indeed, accruing evidence 
suggests that the ACE  gene may modulate the development of complex phenotypes 
through interaction with stimuli such as smoking, where the D-allele has been 
associated with higher CVD mortality (Sayed-Tabatabaei F.A. et al., 2005). The
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previous chapter provided evidence for a possible interaction with lipids in North 
Europe on CHD risk.
Hypertension is another environmental stimulus that could interact with ACE. 
Hypertension and RAS are intimately linked with RAS activation, probably preceding 
its development, but both are likely acting in positive feedback. Angll is heavily 
involved in the vascular remodelling that is a hallmark of the vascular insult in 
hypertension, inducing smooth muscle cell hypertrophy, collagen deposition, 
endothelial dysfunction through ROS production, and cytokine secretion (Albaladejo et 
al., 1994; Touyz et al., 2002; Kakar and Lip, 2007). RAS also plays an important role in 
cardiac hypertrophy through cardiomyocyte hypertrophy (Li et al., 2002) and 
myofibroblast remodeling (Siwik et al., 2001). There is also accumulating evidence for 
Angll in the formation o f atherosclerosis causing matrix deposition (Castoldi et al., 
2003), and increased vascular permeability (Tamarat et al., 2002).
In view o f the systemic effects o f hypertension, with diverse tissues being affected, it is 
not surprising that gene expression is altered, with animal models demonstrating 
changes in gene expression in several pathways including upregulation of growth 
promoters, inhibition o f growth inhibitors, with upregulation of genes involved in RAS 
and Angll signalling (Grayson et al., 2007). These gene expression changes (at a 
transcriptional, translational or post-translational level) may be further magnified by the 
inherent presence o f specific genotypes, which in the context of hypertension are now 
‘harmful’. It is thus very clear to see why, in hypertensive individuals, or groups who 
have higher plasma and tissue levels o f ACE i.e. those that carry the D allele of I/D 
polymorphism), CHD risk is made even higher.
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In Chapter 1, gene variants in other RAS components (Bradykinin Receptor 1 and 2, 
and Angiotensin II Receptor Type 2) were discussed that have been shown to combine 
with blood pressure to raise CHD risk (Jones et al., 2003; Dhamrait et al., 2003). A 
common functional variant in the gene for lipoprotein lipase (LPL) - the S447X 
polymorphism has also demonstrated an interaction with SBP on CHD risk (Talmud et 
al., 2007). In terms o f the I/D polymorphism, the D-allele has been associated with a 
greater LVH in hypertensive subjects (Iwai et al., 1994), and interestingly, an 
interaction with blood pressure may exist, where the D-allele was associated with a 
higher risk o f heart failure amongst hypertensives (Schut et al., 2004).
We therefore hypothesised that ACE  genotype might interact with SBP to determine 
CHD risk. We tested this hypothesis in the Second Northwick Park Heart Study 
(NPHSII), which offers 15 year prospective follow-up study of middle-aged men 
healthy at enrollment. In view o f this similar pattern of gene-blood pressure interaction 
with regard to LPL S447X, the combined effects o f the ACE  I/D and LPL S447X and 
SBP on CHD risk were also determined.
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Methods:
Subjects comprised those recruited from the prospective Second Northwick Park Heart 
Study (NPHSII), which is described in Chapter 2, and in more detail in (Miller et al., 
1995).
DNA was available for 2782 eligible men. Genotypes were determined (as described in 
Chapter 2) by PCR MADGE method fo r^ C £  (O'Dell S.D. et al., 1995) in 
approximately 87% of samples and using TaqMan technology for rs4341 (in complete 
LD with the ACE  I/D polymorphism) as described in (Tanaka et al., 2003) for the 
remaining samples. One DNA array (94 samples) was genotyped for both ACE  I/D and 
rs4341 polymorphisms with 100% concordance.
Statistical Analysis was performed using ‘Intercooled STATA’ (version 8.2, STATA 
Corporation, Texas) by Jackie Cooper. Baseline characteristics were transformed to a 
normal distribution as appropriate. Results are presented as hazard ratios (HR) obtained 
from Cox regression models with their corresponding 95% confidence interval (Cl). All 
models included baseline age as a covariate and were stratified by practice in order to 
take account o f modest differences in the baseline hazard by recruitment site. 
Interactions were tested as deviations from multiplicative effects. Frequencies were 
compared by Chi-squared test. Estimated probabilities were obtained from logistic 
regression models and plotted to illustrate the increase in risk with blood pressure. 
Additive effects were determined by fitting coding genotype according to the number of 
rare alleles carried.
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Results
ACE genotype data was obtained in 2711 men (97% subjects with DNA), whose 
baseline characteristics were not significantly different from the whole group (not 
shown). After 15 years of follow-up, 269 men with ACE genotype had developed CHD. 
Established risk factors were all associated with increased risk of development of CHD 
(Table 4.1). The distribution of genotypes was as expected for Hardy-Weinberg 
equilibrium. As shown in Table 1 there was no significant difference between those who 
developed CHD and those that did not in ACE  genotype distribution (p=0.95) or D 
allele frequency (p=0.81). There was no significant difference in any risk factor between 
the different genotype groups (Table 4.2), in particular for SBP (p=0.97) and DBP
(p=0.82).
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Table 4.1: Baseline characteristics by CHD in NPHSII men with ACE genotyping
Characteristics No CHD 
N=2442
With CHD 
N=269
P value
Age (years) 56.0 (3.4) 56.6 (3.5) 0.008
BM l’(kg/m2) 26.2 (3.4) 26.7 (3.3) 0.01
SBP*(mmHg) 136.7(18.7) 141.4(19.2) <0.0001
DBP (mmHg) 84.3(11.4) 87.0(11.4) 0.0003
Smoking [%(N)J 27.3 (666) 37.2 (100) 0.001
Cholesterol (mmol/L) 5.70(1.01) 6.08 (1.03) <0.0001
T riglyceride*(mmol/L) 1.77 (0.93) 2.05 (1.06) <0.0001
Fibrinogen*(g/l) 2.70 (0.52) 2.80 (0.49) 0.003
CRP*(mg/l) 2.40 (2.43) 3.26 (3.37) <0.0001
Genotype distribution 579/1194/669 64/134/71 0.95
II/ID/DD
D Allele frequency 0.518 0.513 0.81
*geometric mean (approx sd)
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Table 4.2 Baseline characteristics by ACE genotype in NPHSII
11
N=643
ID/DD
N=2068
P value
Age 56.1 (3.4) 56.1 (3.4) 0.94
BMIf 26.2 (3.5) 26.3 (3.3) 0.77
SBPf 137.1 (19.2) 137.1 (18.6) 0.97
DBP 84.7(12.1) 84.6(11.2) 0.82
Smoking 29.6(190) 27.9 (576) 0.40
Cholesterol 5.75 (1.04) 5.73(1.01) 0.74
Triglyceride1 1.80 (0.97) 1.80 (0.94) 0.98
Fibrinogen+ 2.69 (0.52) 2.71 (0.51) 0.37
CRP+ 2.36(2.35) 2.50(2.57) 0.27
tgeometric mean (approx sd)
Since SBP was an established risk factor for development of CHD and there is evidence 
for ACE  genotype SBP interaction in other diseases, their interaction on 15 year risk of 
development of CHD (adjusted for age and practice) was examined. Figure 4.1 
demonstrates analysis of CHD risk for D-allele carriers by quartiles of SBP (additive 
model). In the lower two quartiles there was a trend for a protective effect by the D- 
allele, with thereafter a stepwise rise in risk for the D-allele, such that in the highest 
quartile of SBP (>150mmHg), CHD risk of the D-allele carrier was almost 1.5 times 
that of II homozygotes (genotype SBP interaction for p=0.003). A similar result was 
seen with the dominant model for D-allele (interaction p value 0.004). When the results 
were also adjusted for cholesterol, triglycerides and smoking (classical risk factors for
84
CHD significantly different between cases and controls in NPHSII -  see table 4.1), a 
similar pattern of association was seen (interaction p value 0.004).
Figure 4.1: Hazard Ratio for each additional D allele by quartile of SBP. ID+DD 
[Number of controls/Number developing CHD] v II [Number of controls/Number 
developing CHD]. Reference group is specific for each SBP quartile -  it is the ratio of 
number of individuals with II genotype who develop CHD after 15 years to the total 
number of II controls within the same SBP quartile.
SBP(mmHg) ID/DD vs II
>150 506/78 vs156/15
1.47
138-150 516/50 vs153/13
125-137 524/38 vs171/18
<125 520/39 vs163/18
0 .7
0 .7
p value for linear trend = 0 .003
0 0 .5  1 1.5 2  2 .5
Hazard Ratio DD/ID vs II
When SBP was examined as a continuous variable (Figure 4.2A), the HR for a 1 
standard deviation (SD) increase in SBP was 0.90(0.70-1.15) for IIs and 1.40(1.21-1.61) 
for ID/DD (genotype SBP interaction p=0.002). Thus, compared to the common D- 
allele carriers (66.3% of men), who showed the expected effect of increasing CHD risk 
with increasing blood pressure, the ACE  II men (23.7% of the group) were protected 
from this blood pressure risk effect. Additional adjustment for cholesterol, triglyceride 
and smoking led to a very similar pattern, with the HR for a 1 SD increase in SBP being 
0.85[0.66-1.09] for IIs and 1.32[ 1.14-1.52] for ID/DD (genotype SBP interaction
p=0.002).
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Figure 4.2A: Probability of CHD by SBP in NPHSII subjects stratified by ACE  (I/D) 
genotype. ID+DD [Number of controls/Number developing CHD] = [1863/205] ; II 
[Number of controls/Number developing CHD] = [579/64]
HR for ID/DD 1.40 (1.21 -1.61) p< 0 .0001
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Figure 4.2B: Probability o f CHD by SBP in NPHSII subjects stratified by LPL S447X 
genotype. SX+XX [Number of controls/Number developing CHD] = [483/44] ; SS 
[Number of controls/Number developing CHD] = [2014/175] (Talmud et al., 2007)
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Effect on risk of combined genotypes
The combined effects of the ACE  I/D, LPL S447X and SBP on CHD risk were 
examined. As shown in (Talmud et al., 2007) and in Figure 4.2B, increasing blood 
pressure had a greater effect on risk in X447 allele carriers than in S447 homozygotes 
(interaction significant in categorical analysis). 2665 men were successfully genotyped 
for both polymorphisms. When the men were grouped into LPL SS or SX+XX subjects, 
and stratified by ACE  II or ID+DD groups (Table 4.3 and Figure 4.2C), the commonest 
genotype group of the ACE  D-allele carriers who were also LPL SS homozygotes 
(61.3% of the men), showed the expected effect of increasing CHD risk with increasing 
blood pressure, with a HR for a 1SD increase in SBP of 1.31 (1.12-1.53) p=0.001. As 
would be predicted if the genotype risk effects were additive, the largest effect of 
increasing blood pressure on CHD risk was seen in the ACE D-allele carriers who were 
also LPL X-allele carriers (14.9% of the men) who had a HR of 1.78 (1.30-2.45) 
p<0.0001. By contrast, there was no evidence for a significant effect of increasing blood 
pressure in those with the ACE  II and LPL SS or ACE II LPL SX+XX combined 
genotype, with the HR estimates for both of these groups being significantly lower than 
for their D-allele carrier counterparts (p=0.02 for both comparisons). These results 
demonstrate that a rise in SBP only leads to a significant rise in CHD risk with carriage 
of the ACE  D-allele, with the risk being even greater in those who also carry the LPL X- 
allele. This association was maintained when also adjusting for cholesterol, triglycerides 
and smoking (table 4.4). A similar result was obtained when SBP was analysed as a 
categorical variable (above and below median of 137 mmHg). Carriers o f the D allele 
and X allele had a HR of 0.42 (p=0.02) compared to those with II and SS genotypes in 
the low risk environment (SBP<137 mmHg), but in those with SBP>137mmHg, D and
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X allele carriers had a higher CHD risk compared to their II and SS counterparts with 
HR 1.60 (p=0.10).
Table 4.3: Interaction of SBP as a continuous variable with ACE (1/D) and LPL S447X 
on CHD risk in NPHSII subjects
AC E  I/D LPL S447X HR for 1 SD P value Interaction
(Number of controls with both increase in SBP (adjusted AC E  (I/D) x
genotypes / Number of CHD (95% Cl) for age and LPL S447X x
cases with both genotypes) practice) SBP
II SS (460/54) 0.91 (0.70-1.19) 0.49
SX/XX (110/9) 0.68 (0.33-1.40) 0.29
ID/DD SS (1467/167) 1.31 (1.12-1.53) 0.001 P=0.16
SX/XX (362/36) 1.78 (1.30-2.45) <0.0001
Table 4.4: Interaction of SBP as a continuous variable with ACE  (I/D) and LPL S447X 
on CHD risk in NPHSII subjects with adjustment for age, practice, cholesterol, 
triglycerides and smoking
AC E  I/D LPL S447X HR for 1 SD P value Interaction
(Number of controls with both increase in SBP AC E  (I/D) x
genotypes / Number of CHD (95% Cl) LPL S447X x
cases with both genotypes) SBP
II SS (460/54) 0.87 (0.67-1.14) 0.32
SX/XX (110/9) 0.60 (0.29-1.44) 0.17
ID/DD SS (1467/167) 1.22(1.04-1.44) 0.02 P=0.11
SX/XX (362/36) 1.69(1.23-2.32) 0.001
Figure 4.2C Probability of CHD by SBP in NPHSII subjects stratified by LPL S447X 
and ACE  (I/D) genotype. [For number of samples see table 4.2]
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Discussion
In view of the increasing evidence for the ACE  gene acting as a modifier for CVD 
(Sayed-Tabatabaei F.A. et al., 2005; Schut et al., 2004) and that SBP is a powerful CHD 
risk factor with a large evidence base for worsening and furthering RAS involvement, 
the hypothesis was tested that prospective CHD risk by ACE genotype would be 
influenced by SBP. As expected, no overall genotype risk association was found, but 
analysis by quartiles o f SBP revealed a differing genotype CHD risk based on SBP, and 
possession of the D allele was associated with higher risk when SBP was elevated.
There is a precedent for such a proposed interaction: amongst hypertensive subjects, 
those carrying the ACE  D-allele have been reported to be at higher risk o f heart failure 
(Schut et al., 2004).
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This impact o f the ACE  I/D polymorphism, and its interaction with SBP in determining 
CHD risk, is likely to depend upon associated differences in tissue ACE activity 
(Danser et al., 1995; Rigat.B. et al., 1990), and consequent Angll generation. Angll has 
multiple proatherosclerotic and prohypertrophic properties (Talmud et al., 2007) (Li et 
al., 2002; Wenzel et al., 2001), with LVH being an independent CHD risk factor (Levy 
et al., 1988). Indeed the ACE  D-allele has been associated with a greater LV growth 
response to a variety of stimuli (Lechin et al., 1995)(Estacio et al., 1999)(Montgomery 
et al., 1997) and has been associated with hypertensive LVH (Iwai et al., 1994). ACE 
may also promote atherosclerosis through inactivating bradykinin, a vasodilator with 
anti-fibrinolytic properties (Strauss et al., 2006). Whatever the mechanism, ACE 
inhibition reduces CHD event rate amongst patients with vascular disease (Yusuf et al., 
2000) and is associated with decrease in LVH in hypertensives (Mathew et al., 2001).
The reason why D allele carriers have a higher CHD risk when hypertensive compared 
to when normotensive may be due to combination of the increased Angll (and 
decreased Bradykinin) together with the altered gene expression in the hypertensive 
state. Hypertension activates vascular RAS itself (Reja et al., 2006; Zhou et al., 2003) 
with upregulation of genes in RAS and Angll signaling pathway (Grayson et al., 2007). 
Changes in lipid metabolism gene expression have also been seen, which would also 
support the LPL S447X blood pressure interaction (Grayson et al., 2007).
Whilst the absence of the hypertensive milieu might have accounted for the absence of 
detrimental impact o f the ACE  D-allele on CHD risk amongst those with lower SBP, the 
suggested protective effect o f the D-allele in this group remains unexplained. One might 
postulate that other factors are at work: the D allele may be associated with improved
90
insulin sensitivity (Panahloo et al., 1995) and a mouse model has suggested that greater 
ACE  expression was associated with less weight gain (Heimann et al., 2005). Rather 
than a definitive benefit in this situation, it may be more probable that there is a lower 
risk without the presence o f high blood pressure. For Angll to have a damaging effect it 
may need to be in the setting of hypertension where gene expression has been 
substantially altered, allowing processes such as endothelial dysfunction or LVH to 
have already been instigated. In the context of normotension where there is unaltered 
gene expression with no raised tissue stress, there may be less substrate for raised Angll 
levels (e.g. lower Angiotensin II Receptor Type I density) therefore lower CHD risk. 
Whatever, the effect does not seem to have occurred by chance, being evident in both 
lower quartiles of SBP.
Analysis of the SBP interaction with two gene polymorphisms suggests that only in the 
presence of a harmful environment (e.g. hypertension) do their common variants 
become disease-modifying. Further analysis suggests that the combination of the two 
risk gene variants in the risk environment leads to an even higher risk (but no more than 
expected). One explanation is that the raised LPL activity from the X allele o f LPL 
S447X leads to a greater fatty acid availability and it has been suggested in (Talmud et 
al., 2007), in the context of myocardial and vascular stress e.g. hypertension, this will be 
detrimental, leading to vascular dysfunction or greater LVH, again leading to a higher 
CHD risk. The greater LVH or higher inflammatory stress from both gene variants 
acting together, may in some patients lead to a multiplicative interaction on risk but this 
was not demonstrated in this group of healthy subjects. The demonstration in rodents 
that Angll has also been shown to increase triglycerides (Ran et al., 2004) provides 
more evidence for interaction between these particular gene variants by delivering
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further substrate for LPL. Further studies to examine this in patients, for example with 
heart failure, would be o f interest.
At recruitment no subjects were taking ACE inhibitors, Angll receptor blockers, Beta 
receptor blockers or statins. Adjustment for anti-hypertensive medication use would be 
helpful but this data is unavailable for this prospective study based in general practice. 
Although adjusting for anti-hypertensive use might strengthen the conclusions, the lack 
o f information is unlikely to confound the results. If there was a difference in incidence 
or treatment of hypertension in men by ACE genotype, this would be a potential 
confounder. This would occur if the ACE  I/D polymorphism were associated with 
significant effects on SBP or DBP, however there is no strong evidence for such an 
association in the literature, and no evidence for a difference in mean SBP or DBP by 
ACE genotype in NPHSII men at baseline. Although there is some published evidence 
to suggest that subjects with essential hypertension (Arnett et al., 2006) with different 
ACE  genotype, may respond differentially to treatment with different anti-hypertensive 
medications, unless hypertensive subjects with different ACE genotype were treated 
with different medication, which seems implausible, the reported genotype-medication 
interactions are unlikely to be a confounder o f the associations we see with CHD events.
It is interesting to note (from Figure 4.2 A) that in men with a SBP of below 140mmHg, 
when it is likely that no anti-hypertensives were being used in this cohort, the CHD risk 
of carrying the D allele increased with rising SBP as opposed to carriers o f II genotype. 
This would argue against use of anti-hypertensives confounding the observed results. 
Furthermore, while those who did develop hypertension may have been treated, it
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seems despite this, the CHD risk for individuals with the D allele and II genotype 
remained distinct, and continued as would be predicted.
It is important to note that treatment after CHD event would not confound these results 
since survival is only recorded up to the event. Furthermore in the UK, hypertensive 
middle-aged males asymptomatic for CHD would certainly have been in the minority 
with regard to adequate treatment, especially throughout the 1990s. The use o f anti­
hypertensives in this population, especially ACE-inhibitors would have been low. There 
is certainly no consistent pharmacogenetic interaction between ACE-inhibitors (and 
other anti-hypertensives) and outcome in hypertensive subjects in a recent 
comprehensive review (Arnett et al., 2006).
Another assumption is that these associations are explained by differing levels of ACE 
by ACE  (I/D) genotype. To confirm this, measurement of plasma ACE levels would 
have been useful to look for correlation with genotype and levels, and levels and risk, 
but these measurements had not been made. However, there are strong and consistent 
published data which demonstrate that ACE levels in subjects with the ACE  D allele are 
significantly higher than those with the I allele (Rigat.B. et al., 1990; Danser et al., 1995) 
and this effect remains the most likely direct mechanism.
It is of note that the mean baseline SBP levels in those that remained CHD free (mean 
136.7mmHg for mean age o f 56 years) was substantially higher than in the comparative 
group in the Framingham Heart Study (mean SBP of 129.2mmHg for mean age of 58 
years). The explanation for this is not clear, and may be methodological or due to the 
two groups having different genetic and environmental factors. However the mean SBP
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in this group of healthy men is representative of the UK, since compared with national 
figures (Department o f Health, Health Survey of England (2003) 
http://www.dh.gov.uk/assetRoot/04/09/89/15/04098915.xls), the mean SBP in men in 
England in age groups 45-54 in 1993 and 1994 (the last 2 years at which recruitment 
occurred in NPHS2) were 138mmHg and 136mmHg respectively.
In conclusion demonstration o f GEI in the pathogenesis of complex phenotypes is 
increasingly prevalent, especially with the strength of prospective studies (Humphries et 
al., 2003). Evidence from this study is the first to show interaction between the ACE  
gene and SBP in determining prospective risk of CHD, but replication is required to 
confirm these findings with appropriate pharmacogenetic evaluation.
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Chapter 5: Impact of ACE (I/D) polymorphism on Type 2 Diabetes Mellitus:
Interaction with Obesity 
Introduction
As the RAS exists in relevant metabolically active tissues, namely adipose tissue, 
skeletal muscle and pancreas (Karlsson et al., 1998), it is possible that ACE plays a role 
in the pathogenesis o f T2D. Ang II is known to be diabetogenic, causing insulin 
resistance through several routes (Ogihara et al., 2002). It interferes with insulin 
signalling, has a pro-inflammatory effect on tissue beds causing endothelial dysfunction 
(Hattori et al., 2005), inhibits adipocyte differentiation (Engeli et al., 2003), and causes 
beta cell dysfunction via oxidative stress (Leung and Carlsson, 2005). Intervention to 
disrupt the RAS, by the administration o f ACE-inhibitors or Angiotensin II Receptor 
blockers (ARB), has been shown to prevent the development of T2D in high-risk 
individuals in a meta-analysis (Scheen, 2004). This raises the possibility that individuals 
with genetically lower levels o f ACE may be protected from the development of T2D.
Since plasma and tissue ACE levels are strongly associated with the ACE  I/D 
polymorphism (Rigat.B. et al., 1990; Danser et al., 1995), its impact on T2D risk has 
been widely studied with varying results. The D allele was associated with a higher T2D 
risk (OR=T.52,p=0.02) in a case-control study (Stephens et al., 2005). In those with 
T2D, D allele carriers have poorer outcomes, with a higher risk of MI and renal disease 
(Kennon et al., 1999), and a worse response when starting on an intensive 
hypoglycaemic medication regime (Salonen et al., 2006). Paradoxically, the D allele has
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been associated with a higher insulin sensitivity (Panahloo et al., 1995). There were 
however a number o f studies in which no association has been found between this 
genotype and T2D (Grammer et al., 2006; Schmidt and Ritz, 1997). The majority of 
these studies were limited by being cross-sectional and other usual design flaws with 
gene association studies.
Recently studies have suggested that the ACE gene modulates the development of 
disease phenotypes e.g. CVD and heart failure through interaction with key 
environmental factors e.g. smoking and SBP (Sayed-Tabatabaei F.A. et al., 2005)
(Schut et al., 2004). Evidence from the previous two chapters have suggested interaction 
o f ACE  both with lipids and with SBP on CHD risk. There have been no reported ACE 
GEI influencing T2D, however combined SNP interactions or haplotype effects have 
been reported in diabetic nephropathy (Osawa et al., 2007; Ng et al., 2006).
Only a few GEI have been reported so far in T2D: An interaction between PPARy 
Pro 12Ala and obesity on T2D risk has been determined, with the Ala allele conferring 
protection only in those individuals with lower BMI (under 34 kg/m2) (Florez et al., 
2007a). An interaction between a nonsynonymous polymorphism in APM, (+276G>T) 
and obesity on T2D risk has been demonstrated, with an increased risk associated with 
+276T carriers in the obese men but not in the lean men (Gable et al., 2007b). An 
interaction between lifestyle intervention and TCF7L2 rs7903146(C>T) on T2D risk 
has also been reported but was not statistically significant (Florez et al., 2006).
For T2D, the major environmental determinant of risk is obesity (Resnick et al., 2000) 
(Gable et al., 2006). Adipose tissue (especially when located centrally) is pro-
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inflammatory, secreting TN Fa and IL-6 (Kem et al., 1995; Fried et al., 1998) thereby 
actively worsening insulin resistance and increasing T2D risk.
The hypothesis that men with the low ACE II genotype would be protected from 
developing T2D in a prospective 15 year follow up study was therefore examined. In 
view of the raised inflammatory state in obesity, and Angll being pro-inflammatory, an 
interaction between obesity and ACE  genotype in determining prospective T2D risk was 
also investigated.
Methods:
Subjects were recruited from NPHS2 and detailed elsewhere (Miller et al., 1995) and 
Chapter 2. Out of the initial 3012 recruits, 76 with T2D were excluded, and in 230,
DNA could not be extracted. DNA was therefore available for 2706 eligible men and 
genotype obtained in 2642 subjects (97.5 %). There were only significant differences in 
SBP and fibrinogen between the group o f 230 and 2706 eligible samples but the 
absolute differences were small and unlikely to have made an impact (Table 5.1). There 
were no difference in baseline characteristics between the 64 drop-outs and the 2642 
subjects with ACE  genotype (not shown). Two o f those individuals without T2DM and 
one with T2DM did not have height recorded and so there are missing data on BMI in 
these three individuals. ACE  genotypes were determined as stated in Chapter 2 and 
Chapter 4. Obesity was defined as BMI>30 kg/m2. A dominant genetic model was 
assumed based on the results from previous studies (Salonen et al., 2006; Schut et al., 
2004; Stephens et al., 2005).
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Table 5.1: Baseline characteristics in those with and without DNA
Without
N=230
With
N=2706
P value
Age 56.1 (4.0) 56.0 (3.4) 0.65
BMI+ 25.9 (3.9) 26.2 (3.3) 0.21
SBP* 133.3(18.4) 136.9(18.8) 0.004
DBP 83.1 (11.5) 84.6(11.4) 0.06
Smoking 33.3%(77) 28.4% (769) 0.11
Cholesterol 5.71 (1.05) 5.73(1.01) 0.80
Triglyceride1 1.75 (0.88) 1.78 (0.93) 0.63
Fibrinogenf 2.79 (0.56) 2.71 (0.51) 0.05
CRP+ 2.38 (2.59) 2.46 (2.51) 0.67
tgeometric mean (approx sd)
Statistical Analysis was performed using ‘Intercooled STATA’ (version 8.2, STATA 
Corporation, Texas) by Jackie Cooper as detailed in Chapter 4.
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Results:
ACE  genotype data was obtained in 2642 men. After 15 years of follow-up, 153 men 
with ACE  genotype developed T2D. The remaining 2489 men were alive and had not 
developed T2D. Baseline BMI, obesity, C-reactive protein (CRP), triglyceride, 
cholesterol and blood pressure were all associated with increased risk of development of 
T2D (Table 5.2). Alcohol consumption was not different between those who developed 
T2D and those who did not. The highest risk was that associated with obesity (HR 
3.74(2.66-5.26) p<0.0001). When a stepwise model was used to determine which of 
these variables were independently associated, BMI remained the most significant 
predictor, with an age and practice-adjusted HR for one SD increase, of 1.91 ((1.64-2.24)
p<0.0001).
There was no significant difference between those who developed T2D and those that 
did not, in ACE  genotype distribution (p=0.48) or D allele frequency (p=0.87) (Table 
5.2). Distribution of genotypes was as expected for Hardy-Weinberg equilibrium. HR 
(adjusted for age and practice) for developing T2D for DD+ID vs II was 0.91 (0.63-1.32) 
p=0.63. To eliminate the possibility of confounding it was confirmed that there were no 
significant differences in baseline BMI, blood pressure, lipid parameters, age, CRP or 
alcohol consumption between the different genotype groups (Table 5.3).
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Table 5.2: Baseline characteristics by diabetes in NPHS1I men with ACE  genotyping
No diabetes 
N=2489
With diabetes 
N=153
P value
Age(years) 56.0 (3.4) 56.2 (3.3) 0.53
BMI*(kg/m2) 26.1 (3.3) 28.6 (3.6) <0.0001
Obesity [%(N)1 12.3 (307) 33.6 (51) <0.0001
SBPa(mmHg) 136.6(18.7) 142.2(19.1) 0.0004
DBP(mmHg) 84.5(11.4) 86.5(11.3) 0.03
Smoking[%(N)] 28.2 (702) 35.3 (54) 0.06
Cholesterol(mmol/L) 5.72(1.01) 5.92 (0.98) 0.02
T rigIyceridea(mmol/L) 1.76 (0.92) 2.27(1.05) <0.0001
Fibrinogena(g/l) 2.70 (0.51) 2.77 (0.54) 0.12
CRPa(mg/l) 2.41 (2.46) 3.38 (3.24) 0.0004
Alcohol
% drinkers 80.7 77.8 0.37
Median units/wk 6 [1-16] 5 [1-18] 0.84
[IQR]
Genotype distribution 584/1232/673 39/68/46 0.48
II/ID/DD
D Allele frequency 0.518 0.523 0.87
(95% Cl) (0.504-0.532) (0.465-0.580)
“geometric mean (approx sd); [IQR] -  Interquartile Range
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Table 5.3 Baseline characteristics by ACE genotype in NPHSII
II
N=623
ID/DD
N=2019
P value
Age 56.0(3.4) 56.0 (3.4) 0.99
BMIf 26.2 (3.4) 26.2 (3.3) 0.75
SBPf 137.0(19.1) 136.9(18.6) 0.96
DBP 84.7(12.1) 84.6(11.2) 0.84
Smoking 29.9(186) 28.2 (570) 0.43
Cholesterol 5.75 (1.04) 5.73 (0.99) 0.77
Triglyceride1 1.78 (0.96) 1.78 (0.92) 0.99
Fibrinogen* 2.69 (0.52) 2.71 (0.51) 0.31
CRP+ 2.34 (2.32) 2.49 (2.57) 0.23
Alcohol
0 drinkers 78.3 (488) 81.2(1640) 0.11
Median 7 [1-17] 6 [1-15] 0.55
units/wk
[IQR]
tgeometric mean (approx sd)
ACE  Obesity interaction on T2D risk
Since obesity was the strongest risk factor for development of T2D, and in view of the 
potential for escalating the inflammatory burden in obese individuals, the interaction 
between ACE  genotype and obesity on 15 year risk of development of T2D (adjusted for 
age and practice) was examined. In non-obese men, D allele carriers had a non-
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significantly lower risk o f T2D - HR ID+DD v II 0.69 (0.45-1.06) while in obese men 
the association was reversed, HR ID+DD v II 2.11 (0.95-4.69) with a significant 
genotype-obesity interaction (p=0.02). Figure 5.1 demonstrates that when adjusting for 
triglycerides, CRP and SBP (three strongest predictors of T2DM (table 5.2) which may 
also be causal) the risk of T2D in obese men was similarly higher in D allele carriers 
compared to II homozygotes (HR=4.26(1.30-13.93)), while in lean men there was no 
genotype difference in risk (HR=0.75(0.46-1.22)), with an overall interaction p=0.01.
Figure 5.1: Hazard Ratio (adjusted for age, practice, triglycerides, CRP and SBP) for 
T2D in non-obese and obese NPHSII men by ACE I/D genotype. [Number of 
subjects/Number developing T2DM]
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A Kaplan-Meier plot (Figure 5.2) demonstrates that development of T2D in obese 
subjects occurs much earlier than in non-obese men, with the curve for obese D carriers 
separating from obese II homozygotes between 7-10 years. It also shows that after 15 
years those subjects with the lowest T2D risk are the non-obese D allele carriers.
Adj for age, practice, triglyceride, CRP, SBP 
Interaction pm.01
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Figure 5.2: Kaplan-Meier plot for T2D by ACE  genotype and obesity.
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When analysis was carried out using BMI as a continuous variable the HR for a one 
standard deviation (SD) increase in BMI was found to be higher, but not significantly so 
with ID/DD vs II HR 2.18 (1.83-2.61) vs 1.73 (1.27-2.36) p=0.20. However there was 
clear divergence of risk after BMI>30kg/m (Figure 5.3).
Figure 5.3: Graph illustrating divergence of risk after BMI>30kg/m2 for ID/DD vs II 
with BMI as a continuous variable
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Analysis using BMI in four categories using cut-offs previously reported (Humphries 
S.E. et al., 2006) showed a non-linear pattern of interaction with a threshold effect 
evident, with the D allele being associated with risk of T2D (adjusted for age, practice, 
triglycerides, CRP, SBP) only at high BMI (genotype-BMI interaction p=0.02) as 
demonstrated in Figure 5.4.
Figure 5.4: Categorical Model for BMI Interaction with ACE genotype on prospective 
risk of T2D. ID+DD [Number of subjects/Number developing T2D] v II [Number of 
subjects/Number developing T2D]. Reference group is specific for each BMI category -  
it is the ratio of number of subjects with II genotype who develop T2D after 15 years to 
the total number of II subjects within the same BMI category. Categories of BMI were 
as used in a previous analysis (Humphries S.E. et ah, 2006).
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Discussion:
Based on the protective effect of ACE inhibitors and ARBs on the development of T2D 
in a meta-analysis of large clinical trials (Scheen, 2004), and experimental evidence for 
Angll inducing insulin resistance (Ogihara et ah, 2002), the hypothesis that ACE  II 
subjects, with genetically determined lower ACE levels, would have a lower rate of
4 .2 6
Adj for age, practice, triglyceride, CRP, SBP 
interaction p=4).01
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T2D development was tested. Furthermore an interaction between obesity and I/D 
polymorphism on T2D was examined given the strong pro-inflammatory effect of 
central adiposity and Angll.
An effect was seen, confined to obese men, where D allele carriers had a significantly 
greater risk than their II counterparts, but in non-obese men there was no difference in 
genotype risk. Possession of the D allele, therefore, may be increasingly harmful when 
individuals are obese. Further examination suggested that this was not a linear effect of 
BMI on risk, but rather the effect only became significant once the individual had a 
BMI>30 kg/m2.
The mechanism of the ACE  gene variant and its relationship with obesity in the 
pathogenesis of T2D is currently unclear, but is likely to be due to the impact of the 
different levels of plasma and tissue ACE that will be present constitutively, with the II 
subjects having roughly 40% lower levels than DD subjects (Danser et al., 1995; 
Rigat.B. et al., 1990). The higher serum and tissue ACE associated with the D allele 
would lead to higher Angll levels. The RAS is present in the circulation and several 
tissues in which glucose metabolism are controlled including skeletal muscle, pancreas 
and adipose tissue (Karlsson et al., 1998). There is now considerable evidence for Angll 
promoting the development of T2D through a number of mechanisms (Hattori et al., 
2005; Leung and Carlsson, 2005; Engeli et al., 2003). It is likely that the higher Angll 
levels in D allele carriers would have a bigger impact in the obese state where there is 
already a greater inflammatory and diabetogenic burden (Kern et al., 1995; Fried et al., 
1998).
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It is however important to note the wide 95% Cl limits for D allele carriers (adjusted for 
age, practice, triglycerides, CRP, SBP). This would be in keeping with a small effect of 
the ACE  (I/D) polymorphism on risk of development of T2D which ties in with 
conclusions from the DREAM Trial (DREAM Trial Investigators, 2006) where 
Ramipril did not reduce incidence of T2D in high-risk individuals but suggested a small 
benefit in glucose metabolism.
Adjustments of the ACE  risk effects were made for SBP, triglycerides and CRP because 
with BMI, these were the strongest predictors of T2D development in this cohort. Such 
adjustments did not materially alter the genotype risk pattern seen. All three factors may 
be involved in the same causal pathway in T2D pathogenesis. SBP can directly activate 
the RAS (Reja et al., 2006). Non-esterified fatty acids (from triglyceride hydrolysis) 
directly inhibits insulin signalling (Wang et al., 2006) and excess intracellular 
triglycerides promotes increased oxidative stress and inflammation which can cause 
insulin resistance (Bakker et al., 2000). AngH’s properties of affecting insulin signalling 
and causing oxidative stress would directly affect this. CRP may act together with Angll 
in promoting insulin resistance again through direct and indirect effects on insulin 
signalling and oxidative stress (Xu et al., 2007).
There are several limitations to this study. The method of identification of NPHS1I men 
with T2D, by the medical record search, is unlikely to include any false positive 
diagnosis, but, in the absence of a full recall for fasting glucose testing, some T2D 
subjects may be misclassified as healthy. This would result in an underestimate of the 
15 year incidence of T2D, reducing the ability to detect an effect of the polymorphism, 
and would not confound the genetic association seen.
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The lack of plasma glucose and serum insulin data prevents an exploration of whether 
these parameters are affected by ACE (I/D) genotype, in light of the potential 
detrimental impact of Angll on insulin signalling and glucose metabolism. Background 
diet and physical activity data would have also been useful, as they could affect 
development of T2D.
The incidence of T2D could possibly have been under-estimated in the non-obese 
subjects as a whole, in view of general practioners being more alert to the presence of 
T2D in obese rather than non-obese patients. However, this is unlikely in this sample, in 
view of the thorough, systematic review of patients’ notes and it is worth noting that 
greater than 75% of cases with T2D were from the non-obese group over the 15 years of 
follow-up. Even if this did take place, it is unlikely it would affect the major 
conclusions of the studies, because it is implausible that any such under-estimation of 
T2D would occur by ACE  (I/D) genotype. All of the 2489 subjects without T2D are still 
alive since they are ‘flagged’ with the Office of National Statistics and we receive all 
death certificates. At recruitment no subjects were taking ACE inhibitors, ARBs and 
Beta receptor blockers, and although a proportion of those who developed T2D over 
follow-up may have been prescribed such medications this is unlikely to have 
confounded the genetic effect on risk observed here, but would rather have the effect of 
diluting it.
A further limitation is that the study is underpowered to detect associations in which 
alleles have a small effect. Multiple testing (in this case for interaction and adjustments) 
may raise the probability that ‘chance’ is the explanation for the observed associations
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and these results may therefore be false positives. A similar prospective study of T2D 
was not available to us to try and replicate the findings. Re-analysis of a previously 
published case control study showed a higher risk of T2D in obese D allele carriers 
compared to II subjects but the genotype-obesity interaction is not significant. There 
was however limited power (only 60% to detect the previously observed effect at the 
5% significance level) to demonstrate such an effect size. Studies in which there are 
much larger numbers of cases and controls are necessary for firm conclusions.
In conclusion the work presented here supports the findings that variation in ACE gene 
may interact with BMI to increase the risk of T2D. Further replication is certainly 
required to confirm these findings. The combination of the pro-inflammatory D allele 
and an already ‘at risk’ obese state, may well underlie an impaired metabolic profile and 
a possible increased propensity to T2D.
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Chapter 6: Impact of AC E  (I/D) polymorphism on Hypertrophic Cardiomyopathy
Introduction
Hypertrophic Cardiomyopathy (HCM) is a common genetic heart muscle disorder, 
inherited in an autosomal dominant manner, characterised by unexplained LVH (Maron 
et al., 1995). The clinical course is highly variable, ranging from asymptomatic 
throughout life to premature sudden death, heart failure and arrhythmia. It is the most 
common cause of sudden death in young adults (Maron et al., 1995). There is an 
overall tendency in HCM for gradual wall thinning and a gradual decrease in systolic 
performance over time (Thaman et al., 2004; Thaman et al., 2005).
The majority of causative mutations have been found in sarcomeric protein genes 
(Marian, 2002). HCM exhibits genetic heterogeneity and allelic heterogeneity with 
many mutations found in each gene. Though studies have demonstrated specific 
genotype-phenotype associations (Abchee and Marian, 1997; Charron et al., 1998), the 
majority of phenotypes are not gene specific, with some mutations conferring a mild or 
essentially no phenotype (Ackerman et al., 2005; Watkins et al., 1992; Watkins et al., 
1995). Furthermore, even within affected families (with identical mutations) there is 
definite phenotypic variance (Ashrafian and Watkins, 2007). One explanation for this 
could be presence of other modifier genes e.g in hypertrophic or fibrotic response, or 
environmental factors e.g hypertension, which interact with the causative gene to 
influences the phenotype.
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Searching for ‘modifier’ genes has so far been limited. Polymorphisms in the RAS have 
been most widely studied, since they are good contenders to influence the hypertrophic 
response. The RAS is localised in the myocardium (Danser, 1996), with Angll known to 
induce cardiomyocyte hypertrophy (Li et al., 2002) and pathological remodelling (Siwik 
et al., 2001).
Using the candidate gene association study approach, genes encoding RAS components 
have been shown to modify the phenotypic expression of HCM. With regard to the 
ACE  I/D polymorphism, in a study of 206 patients the DD genotype has been associated 
with higher risk of sudden death (Marian et al., 1993) and increased severity of 
hypertrophy (Lechin et al., 1995), n=183 (Tesson et al., 1997), n=l 14 although other 
studies have demonstrated no association between this polymorphism and HCM 
(Yamada et al., 1997), n=281 (Osterop et al., 1998), n=104. Other SNPs in the RAS -  
^G TM 235T an&AGTR 1166 A/C have been studied, again with mixed results (Ishanov 
et al., 1997; Brugada et al., 1997; Osterop et al., 1998). This is not surprising, in view of 
typical problems associated with such studies including limited sample size and cross- 
sectional heterogenous cohorts. The hypothesis that the ACE I/D polymorphism affect 
HCM phenotypes in a large prospective cohort was therefore tested.
Methods
The study cohort consisted of 541 unrelated patients diagnosed with HCM, assessed at 
St George’s Hospital, London, and Heart Hospital, London UK between 1988 and 2006. 
This is described in Chapter 2.
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Statistical analysis
Statistical analysis was performed using ‘Intercooled STATA' package (version 9.2, 
STATA Corporation, Texas) and LogXact (Version 8) (Cytel Software Corporation, 
Cambridge, Mass). The analysis was performed by Jackie Cooper. Baseline 
associations were analysed by ANOVA when normally distributed (or after appropriate 
transformation), and by Chi-squared or Fisher’s Exact tests when categorical. They are 
presented as mean (standard deviation (SD)). Deviations of allele frequencies from 
Hardy-Weinberg equilibrium were considered using chi-squared tests. Allele 
frequencies are shown with the 95% confidence interval (Cl). Survival analysis was 
undertaken using Poisson regression models. Where the numbers of events were small 
Exact Poisson regression models were fitted. Results are presented as rate ratios (RR) 
along with the rate per 1000 person years of follow-up. The change in echo parameters 
and peak VCT (follow-up -  baseline) was divided by the time between measurements 
for each individual to give the change, per year of follow-up. The mean change 
(standard error SE) by genotype was then estimated from analysis of covariance models 
which included baseline levels to take account of regression to the mean.
Results 
Baseline data
The mean age of the 541 subjects were 38.5 years (SD 17.4). 62.3% (337) were men, 
44.6% (241) were on Beta Blockers (minimum length of 6 months) and 8.3% (45) were 
on ACE inhibitors (ACEI) or Angiotensin 2 Receptor blockers (ARB) (minimum length
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of 6 months). ACE I/D genotype was obtained in 496 subjects (91.6%). The distribution 
of genotypes was as expected for Hardy-Weinberg equilibrium, and the D allele 
frequency was 0.52 (0.49 to 0.56). Genotype association with baseline characteristics is 
shown in Table 6.1 A and B. It demonstrates D allele carriers had smaller LA size, 
smaller LV cavity (lower LVED and LVES), higher FS, max LVWT and pVCK The 
magnitude of difference was modest however, and non-significant.
Table 6.1A ACE genotype association with baseline characteristics (Additive model)
DD
N=141
ID
N=238
II
N=117
P
(trend)
LA 43.8 (7.8) 44.8 (7.8) 45.0(8.3) 0.22
LVED 44.0 (5.2) 43.7 (6.4) 44.4 (6.4) 0.64
LVES 25.3 (5.1) 24.5 (5.9) 25.7 (6.4) 0.62
FS (%) 42.8 (8.0) 44.4 (8.6) 42.5 (9.1) 0.85
MAX LVWT* 20.1 (4.8) 20.5 (5.2) 20.2 (4.7) 0.94
p V 0 2* 20.8 (7.7) 21.5 (9.2) 20.4 (8.6) 0.83
*log transformed
Table 6 .IB ACE genotype association with baseline characteristics (Dominant model)
*log transformed
DD/ID
N=379
II
N=117
P
value
Numbers needed to detect 
significant difference 
(p<0.05) between 
genotype groups with 80% 
power
LA 44.4(7.8) 45.0(8.3) 0.47 8101
LVED 43.8 (6.0) 44.4 (6.4) 0.39 4811
LVES 24.8 (5.6) 25.7 (6.4) 0.13 2081
FS (%) 43.8(8.4) 42.5 (9.1) 0.14 2060
MAX LVWT* 20.3 (5.0) 20.2 (4.7) 0.73 99135
p V 0 2* 21.3 (8.6) 20.4(8.6) 0.39 3975
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Table 6 .IB also demonstrates that in order to detect a significant difference in baseline 
characteristics between the D allele carriers and II homozygotes, a substantial increase 
in the numbers of individuals are needed.
Survival analysis
56 patients were lost to follow-up leaving 485 patients in the survival analysis. There 
were 48 events with 34 deaths (7 cardiac failure, 12 sudden death, 6 other cardiac, 9 
non-cardiac) and 5 transplants, 5 VF, and 4 ICD shock. Median follow-up was 6.65 
years with a range of 0.56 to 19.1 years in those without an event and 5.14 years with a 
range of 0.27 to 16.25 in those with an event (death/VF/transplant). Table 6.2 
demonstrates that those without follow-up were significantly older, had a larger LV 
cavity and lower Max LVWT and pVCL to those with follow-up. This suggests that 
those who were followed up had a more benign phenotype, which would go against 
what would normally occur in a referral centre, in which healthier subjects would be 
discharged, and the more severely affected, remain under follow-up.
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Table 6.2 Baseline characteristics in those with and without follow-up
No follow-up Follow-up P
N=56 N=485 value
Age 45.4(16.7) 37.8(17.3) 0.003
% male 64.3 (36) 62.1 (301) 0.75
% on beta blockers 35.7 (20) 45.7 (221) 0.16
% ACEI/ARB 5.4(3) 8.7 (42) 0.61
LA size 44.5 (9.2) 44.6(7.8) 0.92
LVED 45.6(5.4) 43.7(6.2) 0.04
LVES 26.8(5.6) 24.9 (6.0) 0.03
FS (%) 41.7(8.7) 43.5 (8.7) 0.14
MAX LVWT* 18.6 (4.9) 20.5 (4.9) 0.005
p V 0 2* 23.9 (9.8) 20.8(8.5) 0.03
*geometric mean (approximate SD)
Potential predictors of mortality including age, use of Beta Blockers and ACE inhibitors 
(or ARB) which could confound any genotype effect on mortality were investigated. 
There was no significant effect of age on all-cause or cardiac mortality as demonstrated 
in Table 6.3.
Table 6.3 Effect of age on survival
death/VF/transplant No
N=433
Yes
N=42
RR (95% 
Cl)*
P value
Mean age 37.6 39.0 1.06 (0.97- 0.19
(SD) (17.2) (18.8) 1.16)
death/VF/transplant/ICD No Yes RR (95% P value
shock N=429 N=46 Cl)*
Mean age 37.6 39.2 1.07 (0.98- 0.15
(SD) (17.2) (18.1) 1.16)
cardiac death No Yes RR (95% P value
/VF/transplant N=442 N=33 Cl)*
Mean age 37.7 38.3 1.05 (0.95- 0.36
(SD) (17.2) (19.3) 1.16)
cardiac death No Yes RR (95% P value
/VF/transplant/ ICD 
shock
N=438 N=37 Cl)*
Mean age 37.7 38.6 1.06 (0.96- 0.27
(SD) (17.2) (18.4) 1.16)
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*rate ratio per 5 year increase in age
Use of Beta Blockers was associated with a trend for survival, with regard to cardiac 
mortality with a HR of 0.69 (0.36-1.33) (p=0.27) compared to those not taking it (Table 
6.4). Use of ACE inhibitors (or ARB) was associated with a trend for survival with 
regard to all cause mortality (minus ICD shocks) and cardiac mortality with a HR of 
0.60 (0.12-1.89) (p=0.57) and HR of 0.69 (0.11-2.19) (p=0.77) respectively (Table 6.4). 
Only 42 individuals were on ACE inhibitors however, therefore very few events 
occurred in this group.
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Table 6.4 Events by Beta Blocker and ACE inhibitor (or ARB) use
Beta b lockers N o
N = 2 6 3
Y es
N =221
P
N o. death/VF/transplant 24 20
Rate per 1000 person years o f  fu 13.3 11.8
RR (95%  C l) 1.00 0 .8 8  (0 .4 9 -1 .6 0 ) 0 .6 8
N o. death/VF/transplant/ICD sh ock 25 22
Rate per 1000 person years o f  fu 13.0 13.0
RR (95%  C l) 1.00 0 .93  (0 .5 3 -1 .6 6 ) 0 .8 2
N o .  cardiac death/VF/transplant 22 13
Rate per 1000 person years o f  fu 12.2 7.6
RR (95%  Cl) 1.00 0 .63  (0 .3 2 -1 .2 4 ) 0 .1 8
N o . cardiac death/VF/transplant/ IC D shock  
Rate per 1000 person years o f  fu 
RR (95%  Cl)
23
12.8
1.00
15
8.9
0 .6 9 ( 0 .3 6 - 1 .3 3 ) 0 .2 7
A C E  inhibitors (or A R B ) N o Y es P
N = 4 4 3 N = 4 2
N o .  death/VF/transplant 41 3
Rate per 1000  person years o f  fu 13.1 7.9
RR (95%  C l) 1.00 0 . 6 0 ( 0 . 1 2 - 1 .8 9 ) 0 .5 7
N o .  death/VF/transplant/ICD shock 4 4 4
Rate per 1000  person years o f  fu 14.1 10.7
RR  (9 5 %  C l) 1.00 0 .75  (0 .2 0 -2 .0 7 ) 0 .8 0
N o .  cardiac death/VF/transplant 33 2
Rate per 1000  person years o f  fu 10.5 5.3
RR (95%  C l) 1.00 0 .5 0  (0 .0 6 -1 .9 6 ) 0.51
N o. cardiac death/VF/transplant/ IC D  shock 36 3
Rate per 1000 person years o f  fu 11.6 8.0
RR (95%  C l) 1.00 0 . 6 9 ( 0 .1 1 4 - 2 .1 9 ) 0 .7 7
RR Relative risk; fu Follow-up
O f the 485 with survival data, ACE  genotype was obtained in 446 individuals in which 
46 events occurred. There was no significant mortality difference between D allele 
carriers and II homozygotes, as shown in Table 6.5. Adjustments were made for Beta 
Blocker and ACE inhibitor (or ARB) use only in view of the possible pharmacogenetic 
interaction with ACE  (I/D) genotype on survival, as evident by the trends in Table 6.4,
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and from individuals with heart failure (McNamara et al., 2001; McNamara et al., 
2004).
Table 6.5 Survival analysis by genotype
D D /I D
N = 3 3 7
11
N = 1 0 9
P
N o. death  V F  transplant 33 9
(Rate per 1000  person years  o f  fu) 13.3 12.1
RR (9 5 %  C l) 1.00 0.91 ( 0 .3 8 - 1 .9 5 ) 0 .9 8
Adjusted  RR (95%  C l)* 1.00 0 .93  (0 .3 9 -2 .0 1 ) 1.00
N o . death/VF/transplant/ICD s h o c k 36 10
Rate per 1000  person years o f  fu 14.6 13.6
RR (9 5 %  C l) 1.00 0 .9 3  (0 .4 1 -1 .9 1 ) 1.00
Adjusted  RR (95%  C l)* 1.00 0 .9 7  (0 .4 3 -2 .0 0 ) 1.00
N o . cardiac death/VF/transplant 25 8
Rate per 1000  person years o f  fu 10.1 10.8
RR (9 5 %  C l) 1.00 1.17 (0 .4 6 -2 .6 8 ) 0 .83
Adjusted R R ( 9 5 % C I ) * 1.00 1.12 (0 .4 2 -2 .5 3 ) 0 .9 2
N o . cardiac death/VF/transplant/  IC D  sh o ck 28 9
Rate per 1000  person  years o f  fu 11.3 12.2
RR (9 5 %  C l) 1.00 1.08 (0 .4 5 -2 .3 4 ) 0 .9 8
Adjusted  RR (95%  C l)* 1.00 1 .1 4 ( 0 .4 7 - 2 .4 9 ) 0 .8 7
*adjusted for Beta Blocker use, ACE-inhibitor (or ARB) use.
Effect on Left ventricular remodelling
Of the original 541, only 390 subjects had echo follow-up (median 6.5 years with a 
range of 119 days to 20.4 years). Table 6.6 demonstrates that those without echo follow- 
up were older, and less likely to be on Beta Blockers, which may be consistent with a 
typical tertiary referral centre practice, where younger symptomatic patients are 
followed up, but older less symptomatic patients are reviewed by the referring centre. 
The two groups did not differ in baseline levels of echo parameters.
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Table 6.6 Baseline characteristics in those with and without follow-up echo data
No echo 
follow-up 
N= 151
Follow-up
N=390
P value
Age 42.7(18.7) 36.9(16.6) 0.0007
% male 62.3 (94) 62.3 (243) 0.99
% on Beta Blockers 27.2 (41) 51.4 (200) <0.0001
% ACEI/ARB 5.3 (8) 9.5 (37) 0.11
LA 44.6 (7.7) 44.6 (8.0) 0.99
LVED 44.4 (5.7) 43.8(6.3) 0.27
LVES 25.7 (6.0) 24.8 (6.0) 0.13
FS (%) 42.5 (8.9) 43.6(8.7) 0.19
MAX LVWT* 19.9(4.9) 20.5 (5.0) 0.15
p V 0 2* 21.7 (9.3) 20.9 (8.4) 0.37
*geometric mean (approximate SD)
Table 6.7 shows that in those with echo follow-up there was a highly significant 
propensity for LV remodelling with increase in left ventricular dimensions, drop in 
fractional shortening and thinning o f LV wall.
Table 6.7 LV remodelling in those with echo follow-up
Mean absolute 
change per year / 
mm (se)
P value Percentage
change
(se)
P value
LA 0.33 (0.09) <0.0001 0.63 (0.19) 0.001
LVED 0.35 (0.09) <0.0001 0.82 (0.20) <0.0001
LVES 0.75 (0.09) <0.0001 2.94 (0.39) <0.0001
FS (%) -1.19(0.17) <0.0001 -3.05 (0.41) <0.0001
MAX LVWT -0.08 (0.01) <0.0001 -1.85 (0.30) <0.001
In view of the gradual increase in LV size and wall thinning during follow-up, as shown 
above, and presented elsewhere (Thaman et al., 2004; Thaman et al., 2005) the effect of
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age on annual change in echo dimensions was determined. Table 6.8 demonstrates no 
convincing correlation between age and change in echo dimensions in this cohort.
Table 6.8 Correlation between age and change in echo dimensions
Absolute change Percentage change
Correlation P value Correlation P value
LA r=0.06 p=0.21 r=0.07 p=0.20
LVED r=-0.04 p=0.41 r=-0.04 p=0.40
LVES r=0.05 p=0.37 r=0.05 p=0.33
FS r=-0.09 p=0.07 r=-0.09 p=0.07
MAXLVWT r=-0.06 p=0.25 r=-0.05 p=0.36
Due to the possible effect that Beta Blockers and ACE inhibitor (or ARB) use may have 
on in remodelling as seen in heart failure (Sharpe et al., 1988; Bristow et al., 1996) and 
hypertensive LVH (Mathew et al., 2001), change in echo parameters by Beta Blocker 
and ACE inhibitor (or ARB) use was also examined (Table 6.9). No convincing 
remodelling effect was conferred by either medication in this cohort.
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Table 6.9 Change in echo parameters by Beta Blocker and ACE inhibitor (or ARB) use
LA N A b so lu te  change  
M ean (se)
P value Percentage change  
M ean (sc )
P value
Beta B lockers  
N o  
Y e s  
P value
184  
196
0 . 3 9 ( 0 . 1 3 )
0 . 2 7 ( 0 . 1 3 )
0 .5 2
0 .0 0 2
0 .0 4
0 .7 6  (0 .2 7 )  
0 . 4 9 ( 0 . 2 8 )  
0 .4 9
0 .0 0 6
0 .0 8
ACH inhibitor / A R B  
N o  
Y e s  
P value
3 4 4
37
0 . 3 2 ( 0 . 1 0 )
0 . 5 0 ( 0 . 2 4 )
0 .8 4
0.001
0 .0 4
0 . 6 0 ( 0 . 2 1 )
1 .0 9 ( 0 .4 3 )
0 .65
0 .0 0 5
0 .0 2
L V E D
B eta  B lock ers  
N o  
Y e s  
P value
189
196
0 .3 7  (0 .1 3 )  
0.31 (0 .1 2 )  
0 .7 4
0 .0 0 4
0 .0 0 9
0 . 9 0 ( 0 . 3 2 )  
0 .73  (0 .2 6 )  
0 .6 8
0 .0 0 5
0 .0 0 5
A C E  inhibitor / A R B  
N o  
Y e s  
P value
3 4 9
37
0 .3 3  (0 .0 9 )  
0 .4 4  (0 .2 2 )  
0 .5 2
0 .0 0 0 5
0 .05
0 .7 8  (0 .2 2 )  
1.00 (0 .4 9 )  
0 .5 7
0 .0 0 0 4
0 .05
L V E S
B eta B lock ers  
N o  
Y e s  
P value
188
195
0 . 6 9 ( 0 . 1 3 )  
0 .8 2  (0 .1 4 )  
0 .5 0
<0 .0 0 0 1
<0 .0 0 0 1
2 .8 6  (0 .6 1 )  
3 . 0 6 ( 0 . 4 9 )  
0 .8 0
<0 .0001
<0 .0 0 0 1
A C E  inhibitor / A R B  
N o  
Y e s  
P value
3 4 7
37
0 .7 3  (0 .1 0 )  
0 . 6 9 ( 0 . 2 1 )  
0 .5 4
< 0 .0 0 0 1
0 .0 0 3
2 .8 7  (0 .4 2 )  
2 .5 6  (0 .7 3 )  
0 .6 2
< 0 .0001
0.001
FS
Beta B lockers  
N o  
Y es  
P value
188
195
- 1 . 0 6 ( 0 . 2 1 )  
-1 .3 3  (0 .2 6 )  
0 .43
<0 .0 0 0 1
< 0 .0001
-2 .7 4  (0 .5 3 )  
-3 .4 0  (0 .63 )  
0.43
< 0 .0001
<0 .0 0 0 1
A C E  inhibitor / A R B  
N o  
Y es  
P value
3 4 7
37
- 1 . 1 4 ( 0 . 1 8 )  
-1.01 (0 .2 3 )  
0 .4 4
< 0 .0001
0 .0 0 3
-2 .8 9  (0 .4 5 )  
-2 .7 9  (0 .6 7 )  
0 .33
<0 .0 0 0 1
0 .0 0 0 2
M A X  L V W T
Beta B lockers  
N o  
Y e s  
P value
186
197
- 0 . 3 2 ( 0 . 1 1 )  
-0 .4 5  (0 .0 7 )  
0 .3 3
0 .0 0 2
<0 .0001
- 1 .4 6 ( 0 . 4 8 )  
-2 .25  (0 .3 8 )  
0 .1 9
0 .0 0 3
< 0 .0 0 0 1
A C E  inhibitor / A R B  
N o  
Y es  
P value
3 4 8
3 6
- 0 .3 9  (0 .0 7 )  
-0 .3 3  (0 .0 9 )  
0 .8 4
<0.0001
0 .0 0 0 5
-1 .8 6  (0 .3 3 )  
-1 .7 6  (0 .5 0 )  
0 .9 6
< 0 .0001
0.001
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Change in echo parameters by genotype
Of the 390 with echo follow-up, 362 were successfully genotyped for ACE. The ACE 
effect on left ventricular remodelling was therefore examined (Table 6.10).
Table 6.10 Effect of ACE  genotype on left ventricular remodelling
A CE N A b so lute  change  
M ea n /m m  (se)
P value % change  
M ean (se)
P value
L A D D /I D 27 3 0.31 (0 .10 ) 0 .0 0 4 0 .5 6  (0 .2 3 ) 0.01
II 89 0 . 3 2 ( 0 . 2 1 ) 0.13 0 . 6 6 ( 0 . 4 3 ) 0 .13
P value 0 .9 5 0 .8 8
LVED D D /I D 27 3 0 .2 3  (0 .0 9 ) 0.01 0 . 5 4 ( 0 . 1 9 ) 0 .0 0 6
II 89 0 .6 3  (0 .2 6 ) 0 .02 1 .5 0 ( 0 .6 4 ) 0 .0 2
P value 0 .0 7 0 .0 6
LVES D D /I D 27 3 0 . 7 0 ( 0 . 1 0 ) <0 .0001 2 .7 2  (0 .3 7 ) <0 .0 0 0 1
II 89 0 .8 9  (0 .2 6 ) <0 .001 3 . 6 9 ( 1 . 2 1 ) 0 .0 0 3
P value 0 .43 0 .35
FS D D /I D 2 7 3 -1 .2 0  (0 .2 1 ) < 0 .0001 -3.01 (0 .5 1 ) <0 .0 0 0 1
II 89 -1 .1 8  (0 .3 6 ) 0 .0 0 2 -2.91 (0 .8 6 ) 0.001
P value 0 .9 5 0 .95
M A X D D /I D 27 3 -0 .3 6  (0 .0 7 ) < 0 .0001 -1 .7 0  (0 .3 0 ) <0 .0001
LVW T II 89 - 0 . 4 4 ( 0 . 1 7 ) 0.01 -2 .13  (0 .8 4 ) 0.01
P value 0.61 0 .5 6
ACE  genotype was associated with a trend for change in LVED, with D allele carriers 
having a mean annual increase o f 0.23mm vs 0.63mm in II homozygotes (p=0.07 for 
absolute change and p=0.06 for percentage change), as shown in Figure 6.1. No 
significant genotype differences were observed for the remaining echo parameters.
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Figure 6.1: Effect o f ACE genotype on change in LVED
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These changes in LVED do not differ significantly between those genotyped and not 
genotyped as shown below (Table 6.11).
Table 6.11
ACE Not genotyped 
N=28
Genotyped
N=362
P value
LVED
Absolute change (se) 0.75 (0.22) 0.32 (0.09) 0.25
Percent change (se) 1.63 (0.49) 0.76 (0.21) 0.32
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Effect on change in Peak V 0 2 data
Of the original 541, 461 subjects had baseline pV 02 measurements and 252 had follow 
up pV 02 data (median follow up 4.0 years with a range of 42 days to 13.9 years). Mean 
absolute change per year was -0.39 ml/min/kg (SE=0.23) p=0.08. Table 6.12 shows that 
those without follow-up were older and less likely to be on Beta Blockers at baseline. 
This may be consistent with tertiary referral centre practice, as described earlier.
Table 6.12 Baseline characteristics in those with and without follow-up pV 02 measures.
No follow-up
N=208
Follow-up
N=252
P value
Age 42.0(17.4) 35.1 (15.7) <0.0001
%  male 64.9(135)) 64.3 (162) 0.89
% on Beta Blockers 36.7 (76) 52.4(132) <0.001
% ACEI/ARB 5.8(12) 9.9 (25) 0.10
LA 44.8 (8.5) 44.7 (7.4) 0.90
LVED 44.1 (5.6) 43.8 (6.4) 0.64
LVES 25.4 (5.3) 24.7 (6.2) 0.19
FS (%) 42.7(8.1) 44.2 (9.0) 0.07
MAX LVWT* 19.9(4.7) 20.8 (5.3) 0.08
p V 0 2* 20.9 (9.2) 21.3 (8.1) 0.65
*geometric mean (approximate SD)
Table 6.13 Change in p V 0 2 by ACE-I and Beta Blocker use
pV 02 N Absolute 
change 
Mean (se)
P value
Beta Blockers
No 130 0.23 (0.37) 0.54
Yes 134 -0.90 (0.28) 0.002
P value P=0.01
ACEI / ARB
No 237 -0.35 (0.25) 0.16
Yes 27 -0.55 (0.23) 0.02
P value P=0.62
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O f the 252 with pVCL follow-up, 243 were successfully genotyped for ACE. In this 
cohort there was no significant correlation between age and annual change in pV0 2  (r=- 
0.08 p=0.22). Beta Blocker use was adjusted for, because as demonstrated in Table 6.13, 
their use was associated with a significantly greater drop in pV0 2 .
Table 6.14 Effect o f ACE  genotype on change in pV02
PV 0 2 N Absolute 
change 
Mean (se)
P value
DD/ID 184 -0.45 (0.27) 0.10
II 59 -0.02 (0.51) 0.96
P value unadj. 0.27
P value adj* 0.31
*adjusted for Beta Blocker use
Table 6.14 shows that there was a trend for a greater drop in pV02 in D allele carriers 
than II homozygotes.
Discussion
These results suggest the possibility that the ACE  D allele has a mild association with 
favourable left ventricular dimensions and remodelling in HCM. At baseline, carriage of 
the D allele was non-significantly associated with a smaller LV cavity, greater max 
LVWT, higher FS and pVCE. D allele carriers had a trend for a lower rise in LVED but 
there were no other genotype differences in remodelling. There was no effect on 
mortality. In terms of change in pVCE, there was a trend for this being worse in D allele 
carriers than II homozygotes.
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The underlying mechanism behind the possible remodelling benefit conferred by the D 
allele is unclear. RAS activation, mainly through Angll (but also possibly through 
Bradykinin inactivation), causes high levels of reactive oxygen species which drives 
cardiomyocyte hypertrophy (Wenzel et al., 2001; Li et ah, 2002), fibrosis and 
pathological remodelling (Siwik et ah, 2001). ACE D allele which is strongly associated 
with higher tissue and plasma ACE levels would therefore be predicted to be associated 
with a worse phenotype in HCM. The D-allele has already been associated with a 
greater LV growth response to a variety of stimuli (Estacio et ah, 1999; Montgomery et 
ah, 1997) and has been associated with greater LVH in hypertensive subjects (Iwai et 
ah, 1994). The results here do not tie in with the evidence, albeit inconsistent, that the D 
allele is associated with greater LVH in HCM (Lechin et ah, 1995; Tesson et ah, 1997). 
It is interesting that ACE inhibitor (or ARB) use was associated with a trend for 
improvement in all-cause and cardiac mortality suggesting that RAS activation is 
harmful in HCM, however numbers of events in those on ACE inhibitors (or ARB) 
were very low.
The D allele in this cohort was associated with a higher baseline pVC>2, and pV02 is a 
marker of disease progression in HCM (Sharma et ah, 2000), therefore the D allele may 
be of benefit through non-cardiac mechanisms e.g. skeletal muscle or vascular RAS. 
Indeed the D allele has been associated with greater skeletal muscle strength (Folland et 
ah, 2000) and lower rate o f decline in functional ability (in an elderly cohort) compared 
to II homozygotes (Kritchevsky et ah, 2005). The non-significant association of the D 
allele with greater drop in pVCE however goes against this proposition, but may be 
consistent with the greater muscular efficiency in those with the II genotype
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(Montgomery et al., 1999). The putative explanation for association between D allele 
carriage and baseline pVCE also does not directly explain the possible benefit in 
remodelling by the D allele carriers.
There are several limitations to this study. It was underpowered to demonstrate the 
trends seen at baseline and the survival effect. Despite the cohort being the largest one 
to date of HCM patients in the identification of modifier genes, with an adequate follow 
up period (of median 6.5 years in those where no event occurred), the effect of the I/D 
polymorphism was however still too low to be statistically significant in this sample. 
This was demonstrated by the power calculations in Table 6.1, in which more than 2000 
patients are required to detect a statistically significant difference in baseline FS and 
LVES between D allele carriers and II homozygotes.
The combination of drop-outs (due to genotyping failure) and high number of subjects 
being lost to follow-up, led to substantial drop in numbers, which reduced the power of 
the study further, already with insufficient numbers and mild genetic effect. In the 
baseline analysis, there was a 8% drop out rate leaving only 496 subjects. In the survival 
analysis, there were 56 subjects lost to follow-up and in view of genotyping drop-outs 
there were only 446 individuals with ACE  genotype and survival data. There were even 
less numbers with echo and pVC>2 follow-up data.
The follow-up of survival, echo and pVC>2 data had a very wide range, with some 
individuals having follow-ups o f less than a year, and it is difficult to conceive of a mild 
genetic effect that has a measurable impact within a year. These numbers were however 
small e.g. for echo follow-up, only 10 subjects had follow-up of less than one year. In
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terms o f the echo and pVC>2 data, associations were made with respect to ‘change per 
year’ thus short periods o f follow-up was not a substantial issue.
The majority o f the sample were young adults (mean age 38.5 years) but there were 17 
subjects who were under 16 years old with four subjects under five years old. Though it 
may be argued that paedeatric HCM may behave differently to adult HCM e.g. in LV 
growth it is reasonable to look for an underlying genetic effect on phenotype. This 
cohort had an annual mortality rate o f approximately 1% which is consistent with other 
large HCM cohorts (Elliott et al., 2006). The highly significant remodelling effect in 
this cohort, demonstrated in others (Thaman et al., 2005) is further evidence that this 
sample is comparable to others in the literature.
It may well be the case that the ACE  I/D polymorphism is not having a clinically 
important effect in HCM, however studies have also looked at polymorphisms in RAS 
as a candidate system demonstrating a cumulative influence on hypertrophy (Ortlepp et 
al., 2002; Perkins et al., 2005), though in the latter study this was only evident in the 
subgroup with no previously identified mutation. A recent study has demonstrated a 
cumulative effect o f several polymorphisms in RAS genes -A C E  I/D, AGTM 235T, 
CMA- 1903 A/G, AGTR\ 1666 A/C and CYP11B2-344 C/T - on LVH prospectively in a 
group o f paediatric HCM patients (Kaufman et al., 2007). In this cohort, it would 
therefore be useful to genotype these other polymorphisms and combine this 
information to evaluate this in adult HCM subjects. Further work would be to 
specifically identify the causative HCM mutation in these subjects, investigating 
whether candidate polymorphisms only modify phenotypes in those individuals with 
particular sarcomeric mutations for example.
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In conclusion, the results presented here suggest that the D allele o f the ACE  I/D 
polymorphism may be associated with a small effect on LV remodelling in HCM, 
however replication in a larger study with evaluation of other candidate polymorphisms 
is essential.
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Chapter 7: Discussion
This thesis has presented evidence demonstrating the effect of the ACE  I/D 
polymorphism in influencing the risk o f complex phenotypes, namely CHD and T2D, in 
the presence o f common environmental stimuli. There is good biological plausibility for 
this in that (1) ACE is a key component of the RAS, (2) RAS has been found in many 
tissues implicated in these diseases, (3) Angll (and other components) have been shown 
to be disease modifying and (4) there is clinical evidence for benefit of ACE inhibitors 
in CHD and possibly T2D. This polymorphism may also be having a mild beneficial 
effect on ventricular remodelling in HCM. It is important to note it is probably not the 
ED polymorphism that is causing differences in risk but a gene variant which is in 
strong LD with it.
ACE-Lipid interaction on CHD risk in North Europe:
As Figure 7.1 demonstrates, there is an interaction between ACE  genotype and lipid trait 
(triglycerides or apoB) in North Europe, where within North Europe, D allele carriers 
with higher triglycerides or apoB had a higher CHD risk compared to their II 
homozygote counterparts. Furthermore, D allele carriers with these elevated lipid traits 
had higher CHD risk than their D allele counterparts in South Europe. An interaction 
between ACE  and apoB has been previously reported where D allele carriage was 
associated with higher CHD risk, in those with low apoB levels and low BMI (Cambien 
et al., 1992).
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The mechanism for the greater risk conveyed by the D allele with higher apoB in the 
North may be due to a positive feedback mechanism of Angll and cholesterol with each 
other (Keidar et al., 2001). The triglyceride interaction may be due to an ‘Angll raising’ 
effect (Ran et al., 2004). The protective mechanism in the South is yet to be established 
but may be due to other genetic or environmental influences. The difference in CHD 
risks were more substantial for higher apoB levels than for higher triglycerides.
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Figure 7.1 M echanism  o f  ACE  Lipid interaction
(Dotted line between TG (triglyceride) and Angll represents less evidence available for 
a direct interaction)
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ACE -  SBP interaction on CHD risk
In Chapter 4, in a prospective study of healthy middle-aged men, D allele carriers who 
had higher SBP had a greater CHD risk than II homozygotes with higher SBP. The 
excess risk in the D allele carriers has been ascribed to the detrimental tissue effects of 
raised Angll (and lower Bradykinin) -  including that of vascular remodelling, inducing 
a pro-inflammatory and pro-hypertrophic state, adhesion molecule up-regulation,- 
thereby worsening the already ‘stressed’ hypertensive tissue environment (as shown in 
Figure 7.2).
Figure 7.2: Mechanism o f ACE  SBP interaction (BRK Bradykinin)
J ,  Ang II ^  Ang II
HYPERTENSIVE 
ENVIRONMENT : 
VASCULAR  
REMODELLING AND 
LVH
BRK
Pro-inflammatory 
+ up-regulation 
of adhesion 
molecules
LOWER CHD RISK HIGHER CHD RISK
I D / D D
Figure 7.3 demonstrates the combined pro-inflammatory and pro-hypertrophic 
influences of LPL S447X X allele and ACE  D allele carriers on the hypertensive state 
to further increase CHD risk. There is direct evidence for interaction between these two
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variants with Angll also causing an increase in triglycerides (Ran et al., 2004). The 
putative mechanism for raised triglycerides (in LPL447 X allele carriers) being harmful 
in hypertension (as opposed to normotension) is interesting. During ischaemia, in order 
to conserve ATP there is a switch from myocardial triglyceride to glucose metabolism 
(Neely et al., 1972; Allard et al., 1994), so similarly in hypertension,where there is 
raised tissue stress (e.g in myocardium and vascular endothelium), triglyceride 
metabolism may be unfavourable. Thus in hypertensive 447X allele carriers, the raised 
triglyceride levels would presumably prevent shift to glucose metabolism and be 
energetically inefficient possibly promoting further damage (Talmud et al., 2007).
Figure 7.3 Mechanism of combined LPL ACE  SBP interaction
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REMODELLING AND 
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ACE -  Obesity interaction on T2D risk
D allele carriers in NPHS2 who are obese have been shown to have a greater T2D risk 
than their II counterparts. The suggested explanation for this was the multiple 
diabetogenic effects of the raised Angll levels on the already susceptible obese state 
thereby further raising the T2D risk (as demonstrated in Figure 7.4).
Figure 7.4 Mechanism of ACE  Obesity interaction
I D / D D
^  Ang II J ,  Ang
beta cell dysfunction + 
pro-inflammatory
Inhibits adipogenesis
HIGHER T2D RISK LOWER T2D RISK
ACE effect in HCM
The mechanism underlying the smaller left ventricular cavity size and wall thickness at 
baseline, and the lower increase in LVED, in D allele carriers is unclear, given that the 
greater ACE activity (associated with D allele) is correlated with greater cardiac
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hypertrophy. Though the D allele may be associated with greater muscular strength 
which could explain the higher baseline pVC>2, this does not explain the association with 
favourable ventricular dimensions. It is important to state that all these associations 
were statistically non-significant so they may indeed be no effect of this polymorphism 
in HCM.
Limitations
There are several limitations that have been associated with the results presented in this 
thesis. They have been specifically mentioned in the discussions of each chapter 
however a summary of the most important ones will be mentioned here.
For Chapter 3, the majority o f effects seen are not statistically significant, however the 
numbers within the study were too low to pick up the modest genetic effect that was 
being hypothesised. The case-control design allows error from possible survivor bias. 
The other main source o f error relates to the use of medication in cases, which would 
affect blood pressure but most importantly lipid levels in this association.
The most important limitations o f the NPHS2 study (Chapters 4 and 5) included the low 
number of cases, and the lack o f data regarding details of medication. A huge strength 
of the study was the prospective design but because it recruited healthy men, and CHD 
and T2D have a low annual rate, despite 15years of follow-up, there were only a few 
hundred cases. In terms o f lack o f medication data, this is important in that effects of the 
ACE  genotype may be confounded by ACE inhibitors and other anti-hypertensives
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however there is as yet no consistently observed effect between I/D genotype, 
medication and trait.
Effects of ACE on HCM (Chapter 6) was carried out in an observational study which 
was also limited by numbers, approximately 500, though it is the largest cohort of 
HCM patients in which modifier genes have been studied reporting to date. The loss of 
follow up in survival data, but mainly in echo and pV0 2  measurements, further reduced 
the power o f the study to detect an effect o f this polymorphism. The causative mutation 
was unknown in the majority o f the cohort and this may be important in identifying 
precise gene-gene interactions in determining phenotype. Only limited basic 
measurements o f LV size, function and wall thickness were available. 17 of the cohort 
were under 16 years o f age and three individuals were under three years old though it is 
very unlikely that the genetic effects would differ between the paedeatric and adult 
populations.
The absence of measurements o f intermediate traits such as plasma RAS components 
and the use of multiple statistical testing are two limitations throughout this thesis. ACE 
levels would have been useful in determining the link between genotype, trait and risk, 
however the association between ACE  I/D genotype and ACE levels has been 
consistently demonstrated. The multiple testing, including the use of interactions do 
increase the false positive rate, however there were a-priori hypotheses that genotype 
would only have environment-dependent effects, with biological evidence for strong 
prior probability, therefore the need to adjust for multiple testing is unnecessary and 
would also increase false negative rate.
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Further studies
It is important that the key findings in this thesis are replicated in further studies with 
similar design and specifically targeted interactions. In view of the modest effect of the 
ACE  I/D polymorphism which has a context dependent effect, very large prospective 
studies should be carried out where sufficient numbers of cases will occur. The cohorts 
should be phenotyped in a detailed manner including plasma and/or mRNA levels of 
RAS components and with extensive numbers of biomarkers e.g. of the inflammatory 
pathway. Endothelial function and LV mass can be measured as relevant intermediate 
traits and repeated at regular intervals. Ideally the cohort should be kept homogenous 
with regard to age, gender and especially to race, in that the I/D polymorphism does not 
associate with ACE levels in black Africans. Medications with doses and duration 
should be recorded.
Rodent models can be used to further define the mechanisms underlying the suggested 
interactions. Examples of such models in the study of atherosclerosis and hypertension 
include the APOE  knockout mouse (Plump et al., 1992) which develop dyslipidaemia 
and atherosclerosis, and the Spontaneously Hypertensive rat (SHR) (Samani et al., 1989) 
which develop hypertension, LVH, RAS activation and insulin resistance. For the ACE  
lipid interaction, Keider et al (2001) demonstrated that when Angll was infused into 
APOE knockout mice, peritoneal macrophages increased oxidised LDL degradation 
compared to placebo. This effect was blocked by administration of Losartan, an ARB. 
Further experiments could quantify apoB levels and examine whether these mice had 
even more atherosclerosis than placebo. If these mice do get more atherosclerosis then 
they can be then randomised to a chow diet enriched with different oils (Calleja et al.,
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1999) such as virgin olive oil or sunflower oil (i.e. a Mediterranean diet or Southern 
European environment stimulus), a normal chow diet (5% cholesterol) and an 
atherogenic diet ( ‘Paigen’ diet -  (Paigen et al., 1985)) to help determine mechanism 
underlying North South Europe interaction.
For the ACE  SBP interaction, SHR can be infused with Angll to see if they develop 
more atherosclerosis or LVH than SHR alone. Rodent models cannot be used to study 
the ACE  Obesity interaction in T2D because Angll has the opposite effects in rodents of 
promoting adipocyte differentiation (Saint-Marc et al., 2001). Sharma et al has 
suggested further studies to address the deleterious effect of RAS in obesity through 
performing fat biopsies from obese humans before taking, and whilst taking ARB, to 
investigate whether adipocyte size was reduced, and insulin resistance improved while 
ARB were being taken (Sharma et al., 2002).
To examine the ACE  effect in HCM, again a very large, ideally homogenous and well 
phenotyped cohort o f patients are required, which would need a multi-centre, and 
perhaps multi-national consortium. Knowledge of the causative mutation in each 
individual would be helpful. Long term follow-up would enable assessment of genotype 
impact on survival and remodelling. Regular and detailed cardiac assessment through 
echocardiography or magnetic resonance imaging would be necessary for this. In large 
families, ACE  and other candidate RAS genotypes could be compared between 
members who have the causative mutation but no phenotype and those who have the 
causative mutation with phenotype.
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With regard to the genetic effect, a tagging SNP haplotype approach to ACE  can be 
done, though whether this is better than the I/D polymorphism at marking ACE levels in 
Caucasians needs to be convincingly established first. To look at the combined genetic 
effect o f the RAS, functional polymorphisms, where possible tagging SNPs in each 
gene can be combined, to look for gene-gene interactions that have the largest RAS 
effect i.e. highest A ngll and lowest Bradykinin.
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